1
Status: Approved ,  Date: 16 March 2020Janssen Vaccines & Prevention B.V.*
Clinical Protocol
A Randomized, Double -blind, Placebo -controlled Phase 2a Study to Evaluate a Range of 
Dose Levels of an Ad26.RSV.preF -based Vaccine in Adults Aged 60 Years and Older
Protocol VAC18193RSV2005 ; Phase 2a
VAC18193 (JNJ -64400141/JNJ-64213175)
*Janssen Vaccines & Prevention B.V. is a Janssen pharmaceutical company of [COMPANY_012] and is hereafter
referred to as the sponsor of the study. The sponsor is identified on the Contact [CONTACT_233817].
[LOCATION_002] (U S)sites of t his study  will be conducted under US Food & Drug Administration
Investigational New Drug ( IND)regulations (21 CFR Part 312).
Status: Approved
Date: 16March 2020
Prepared by: [CONTACT_130328] & Prevention B.V.
EDMS number: EDMS- ERI-201635401, 2.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements.
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidentia l and 
may not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed
by [CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
[STUDY_ID_REMOVED]
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
2
Status: Approved ,  Date: [ADDRESS_282179] OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 4
1. PROTOCOL SUMMA RY..................................................................................................................... 5
1.1. Synopsis ........................................................................................................................................... 5
1.2. Schema .......................................................................................................................................... 12
1.3. Schedule of Activities ..................................................................................................................... 13
1.3.1. Cohort 1 ...................................................................................................................................... 13
1.3.2. Cohorts 2 and 3 .......................................................................................................................... 15
2. INTRODUCTION ................................................................................................................................ 17
2.1. Study Rationale .............................................................................................................................. 17
2.2. Background .................................................................................................................................... 17
2.2.1. Ad26.RSV.preF and RSV preF Protein Nonclinical Studies ....................................................... 18
2.2.2. Ad26.RSV.preF and RSV preF Protein Clinical Studies ............................................................ 18
2.3. Benefit -risk Assessment ................................................................................................................. 20
2.3.1. Known Benefits ........................................................................................................................... 20
2.3.2. Potential Benefits ........................................................................................................................ 20
2.3.3. Known Risks ............................................................................................................................... 21
2.3.4. Potential Risks ............................................................................................................................ 21
2.3.5. Overall Benefit -risk Assessment ................................................................................................ .23
3. OBJECTIVES A ND ENDPO INTS ..................................................................................................... 25
4. STUDY DESIGN ................................................................................................................................ 27
4.1. Overall Design ................................................................................................................................ 27
4.2. Scientific Rationale for Study Design ............................................................................................. 29
4.2.1. Study-Specific Ethical Design Considerations ........................................................................... 30
4.3. Justification for Dose Level ............................................................................................................ 30
4.4. End of Study Definition ................................................................................................................... 31
5. STUDY POPUL ATION...................................................................................................................... 31
5.1. Inclusion Criteria ............................................................................................................................ 31
5.2. Exclusion Criteria ........................................................................................................................... 32
5.3. Lifestyle Considerations ................................................................................................................. 35
5.4. Screen Failures .............................................................................................................................. 35
6. STUDY VA CCINE .............................................................................................................................. 35
6.1. Study Vaccine Administration ........................................................................................................ 35
6.2. Preparation/Handling/Storage/Accountability ................................................................................ 36
6.3. Measures to Minimize Bias: Randomization and Blinding ............................................................. 37
6.4. Study Vaccine Compliance ............................................................................................................ 38
6.5. Concomitant Therapy ..................................................................................................................... 39
6.6. Intervention After the End of the Study .......................................................................................... 39
7. DISCONTINUA TION OF STUDY VA CCINA TION A ND PA RTICIPA NT 
DISCONTINUA TION/WITHDRA WAL............................................................................................... 40
7.1. Discontinuation of Study Vaccination ............................................................................................. 40
7.2. Contraindications to Study Vaccination ......................................................................................... 40
7.3. Study Vaccination Pausing Rules .................................................................................................. 40
7.4. Participant Discontinuation/W ithdrawa l From the Study ................................................................ [ADDRESS_282180] to Follow -up............................................................................................................................ 43
8. STUDY A SSESSMENTS AN D PROCEDURES ............................................................................... 43
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
3
Status: Approved ,  Date: 16 March [ZIP_CODE].1. Immunogenicity Assessments ....................................................................................................... 45
8.2. Safety Assessments ....................................................................................................................... 46
8.2.1. Physical Examinations ................................................................................................................ 46
8.2.2. Vital Signs ................................................................................................................................... 46
8.2.3. Clinical Safety Laborator y Assessments .................................................................................... 47
8.3. AEs and SAEs ................................................................................................................................ 48
8.3.1. Time Period and Frequency for Collecting AE and SAE Information ......................................... 48
8.3.2. Method of Detecting AEs and SAEs ........................................................................................... 49
8.3.3. Follow -up of AEs and SAEs ....................................................................................................... 50
8.3.4. Regulatory Reporting Requir ements for SAEs ........................................................................... 50
8.3.5. Pregnancy ................................................................................................................................... 50
8.4. Treatment of Overdose .................................................................................................................. 50
8.5. Genetics ......................................................................................................................................... 51
8.6. Medical Resource Utilization and Health Economics .................................................................... 51
9. STATISTICA L CONSIDER ATIONS .................................................................................................. 51
9.1. Statistical Hypotheses .................................................................................................................... 51
9.2. Sample Size Determination ........................................................................................................... 51
9.2.1. Immunogenicity (Cohort 1) ......................................................................................................... 51
9.2.2. Safety (Cohorts 1, 2, and 3) ....................................................................................................... [ADDRESS_282181] ..................................................................... 55
10. SUPPORTING DOCUMENT ATION A ND OPERA TIONA LCONSIDERA TIONS ............................ 56
10.1. Appendix 1: Abbreviation s............................................................................................................. 56
10.2. Appendix 2: Toxicity Grading Scale ............................................................................................... 57
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting ............................................................................................................... 61
ADVERSE EVENT DEFINITIONS AND CLASSIFICATIONS .............................................................. 61
ATTRIBUTION DEFINITIONS .............................................................................................................. 62
SEVERITY CRITERIA .......................................................................................................................... 62
SPECIAL REPORTING SITUATIONS ................................................................................................ .62
PROCEDURES .................................................................................................................................... 63
CONTACT[CONTACT_233818] ............................................................................. 64
PQC HANDLING .................................................................................................................................. 64
10.4. Appendix 4: Regulatory, Ethical, and Study Oversight Considerations ......................................... 66
REGULATORY AND ETHICAL CONSIDERATIONS .......................................................................... 66
FINANCIAL DISCLOSURE .................................................................................................................. 69
INFORMED CONSENT PROCESS ..................................................................................................... 69
DATA PROTECTION ........................................................................................................................... 70
LONG -TERM RETENTION OF SAMPLES FOR ADDITIONAL FUTURE RESEARCH ...................... 70
COMMITTEES STRUCTURE .............................................................................................................. 71
PUBLICATION POLICY/DISSEMINATION OF CLINICAL STUDY DATA ........................................... [ADDRESS_282182] RETENTION ........................................................................................................................ 74
STUDY AND SITE START AND CLOSURE ........................................................................................ 75
10.5. Appendix 5: Protocol Amendment History ..................................................................................... 76
11. REFERENCES ................................................................................................................................... 77
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
4
Status: Approved ,  Date: [ADDRESS_282183] OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Overview of Clinical Studies With Ad26.RSV.preF ................................................................... 19
Table 2: Overview of the Cohorts, Groups, and Targeted Number of Participants ................................ 27
Table 3: Summary  of Possible Immunogenicity Assays (Humoral and Cellular) ................................... 45
Table 4: Protocol -required Clinical Laboratory Assessments ................................................................ .47
Table 5: Upper Limit of the 95% One -sided Confidence Interval if no Cases are Observed for 
Different Sample Sizes ............................................................................................................. 52
Table 6: Probability of Observing at Least One AE in a Group of the Considered Sample Size 
Given Several True AE Rates ................................................................................................... 52
FIGURES
Figure 1: Schematic Overview of the Study ............................................................................................. 12
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
5
Status: Approved ,  Date: 16 March [ZIP_CODE].PROTOCOL SUMMARY
1.1. Synopsis
A Randomized, Double -blind, Placebo -controlled Phase 2a Study to Evaluate a Range of Dose 
Levels of an Ad26.RSV.preF -based Vaccine in Adults Aged 60 Years and Older
The respi[INVESTIGATOR_4345] ( RSV )vaccine that will be investigated in the current study, the 
Ad26/protein preF RSV vaccine (VAC18193), is a combination of 2 vaccine components, administered as 
a single intramuscular (IM) injection:
 Ad26.RSV.preF (JNJ-64400141), a replication -incompetent adenovirus serotype 26 (Ad26) 
containing a DNA transgene that encodes the prefusion conformation- stabilized F protein (preF) 
derived from the RSV A2 strain.
 RSV preF protein (JNJ -64213175), a recombinant preF protein derived from the RSV A2 strain.
The aim of this dose- ranging study is to determine the safety and immunogenicity of different dose levels 
of Ad26.RSV.preF in the Ad26/protein preF RSV vaccine to support the refinement of the acceptance 
criteria for drug product release and stability by [CONTACT_233819] (for 
the upper release limit) and immunogenicity (for the lower release limit) .
OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Cohort 1
Primary
 To explore the dose-response relationship of 
humoral immune responses induced by 
[CONTACT_233820]26 .RSV. preF-
based vaccine Antibody titers to RSV preF protein using 
preF enzyme -linked immunosorbent assay 
(ELISA ) at 14 days after vaccination
Secondary
 To explore the dose-response relationship of 
humoral and cellular immune responses 
induced by [CONTACT_233821]26 .RSV. preF- based vaccine Antibody titers to RSV preF protein using 
preF ELISA at 3 and 6 months after 
vaccination
 RSV A2 neutralizing antibody levels at 
14days and 3 and 6 months after 
vaccination
 Interferon (IFN)-γ enzyme -linked 
immunospot (ELISpot )assay at 14 days 
and 3 and 6months after vaccination
 To assess the safety and reactogenicity of 
different dose levels of theAd26 .RSV. preF-
based vaccine Serious adverse events (SAEs )from the 
time of vaccination until the end of the 
study
 Solicited local and systemic adverse events 
(AEs)from the time of vaccination until 
7days after vaccination
 Unsolicited AEs from the time of 
vaccination until 28 days after vaccination
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
6
Status: Approved ,  Date: 16 March 2020Objectives Endpoints
Cohort 1
Exploratory
 To explore additional vaccine -elicited immune 
responsesAssays that may be used include, but are not 
limited to:
 Post-Fprotein binding antibodies (ELISA)
 Antigen-specific T- cell immune responses
 RSV cross -neutralization of B and/or other 
A strain(s)
 Anti- F protein antibody specificity 
characterization
 Analysis of immunoglobulin (Ig)A and/or 
IgG antibodies binding to RSV F protein in 
prefusion and/or postfusion form in nasal 
samples
 Analysis of neutralizing antibodies to Ad26
Objectives Endpoints
Cohorts 2 and 3
Primary
 To assess the safety and reactogenicity of 
different dose levels of theAd26 .RSV. preF-
based vaccine Solicited local and systemic AEs from the 
time of vaccination until 7 days after 
vaccination
 Unsolicited AEs from the time of 
vaccination until 28 days after vaccination
Secondary
To assess the humoral and cellular immune 
responses induced by [CONTACT_233822]26 .RSV. preF- based vaccine Antibody titers to RSV preF protein using 
preF ELISA at 14 days and 3 and 6months 
after vaccination
 RSV A2 neutralizing antibody levels at 
14days and 3 and 6 months after 
vaccination
 IFN-γ ELISpot assay at 14 days and 3 and 
6months after vaccination
To assess the safety of different dose levels of 
theAd26 .RSV. preF- based vaccine SAEs from the tim e of vacci nation until the 
end of the study
Exploratory
 To explore additional vaccine -elicited immune 
responsesAssays that may be used include, but are not 
limited to:
 Post-Fprotein binding antibodies (ELISA)
 Antigen-specific T- cell immune responses
 RSV cross -neutralization of B and/or other 
A strain(s)
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
7
Status: Approved ,  Date: 16 March 2020Hypothesis
No formal statis tical testing of safety orimmunogenicity data is planned ; data will be analyzed 
descriptively.
OVERALL DESIGN
This is a randomized, double- blind, placebo -controlled, multicenter, interventional Phase 2a study in male 
and female adults aged ≥60 years who are in stable health, to explore the dose-response relationship, 
safety , and immunogenicity of a range of dose levels of the Ad26.RSV .preF -based vaccine . Participants 
will be randomly assigned to different dose levels of Ad26.RSV .preF in the Ad26/protein preF RSV  
vaccine or to placebo in 3 cohorts .Thestudy vaccine will be administered asa single IM injection.
Cohort Group N Day 1 (Vaccination)
1(dose -down) 1 50 Ad26.RSV.preF 1×1011vp + RSV preF protein 150 μg
2 50 Ad26.RSV.preF 3.3×1010vp + RSV preF protein 150 μg
3 50 Ad26.RSV.preF 1.1×1010vp + RSV preF protein 150 μg
4 50 Ad26.RSV.preF 3.7×109vp + RSV preF protein 150 μg
5 25 Placebo
2(dose -up) 6 50 Ad26.RSV.preF 1×1011vp + RSV preF protein 150 μg
7 50 Ad26.RSV.preF 1.3×1011vp + RSV preF protein 150 μg
8 25 Placebo
3(dose -up) 9 25 Ad26.RSV.preF 1×1011vp + RSV preF protein 150 μg
10 50 Ad26.RSV.preF 1.6×1011vp + RSV preF protein 150 μg
11 25 Placebo
N = number of participants ; vp = viral particles .
The study duration will be approximately [ADDRESS_282184] participant’s last visit . 
An internal Data Review Committee (DRC) will be commissioned for this study , and pre-specified study 
vaccination pausing rules will be applied to ensure safety of the participants .
In the dose-down cohort (Cohort 1), a target of approximately 225participants will be randomized in
parallel ina 2:2:2:2:1 ratio to5 groups . In the dose-up Cohort 2,a target of approximately 
125participants will be randomized in parallel in a 2:2:1 ratio to3groups .Inthe dose-up Cohort 3, a 
target of approximately 100 participants will be randomized in parallel in a 1:2:1 ratio to3 groups.
Cohorts 1 and 2 may be enrolled in parallel ,whereas Cohorts 2 and 3 will be enrolled in a staggered 
manner .A study site will not simultaneously enroll participants in more than onecohor t.
Initially , a sentinel group of 5participants will be enrolled in Cohort 2 in a 2:2:1 ratio to Groups 6to 8, 
respectively, before enrolling additional participants (Step 1). Ablinded 24-hour postvaccination safety 
review will be performed by [CONTACT_191722](s) (PI[s]) and sponsor team members (ie, at least 
thestudy responsible physician /study responsible scientist). Inthe absence of any clinical safety concerns , 
anadditional 15participants will be enrolled in a2:2:1 ratio (Step 2). After review of the 7-day(Day 8)
postvaccination safety data of these 20participants by [CONTACT_16009] , the remaining participants in the cohort  Anti- F protein antibody specificity 
characterization
 Analysis of IgA and/or IgG antibodies 
binding to RSV F protein in prefusion 
and/or postfusion form in nasal samples
 Analysis of neutralizing antibod ies to Ad26
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
8
Status: Approved ,  Date: 16 March 2020will be randomized in a 2:2:1 ratio (Step 3).When all participants in Cohort [ADDRESS_282185] 7 days after vaccination
of all participants in the cohort will be reviewed by [CONTACT_16009]. Based on this review, the sponsor may
decide to notinitiate enrollment of Cohort 3.
The enrollment of Cohort 3 will be conducted similarly to Coho rt 2. Steps 1 and 2 will be performed with 
a sentinel group of 4 participants and with 12 participants, respectively, both enrolled in a 1:2:1 ratio. 
After review of the 7-day (Day 8) postvaccination safety data of these 16 participants by [CONTACT_16009], the 
remaining participants in the cohort will be randomized in a 1:2:1 ratio.
After vaccination with study vaccine on Day 1, participants will remain under observation at the study 
site for a minimum of 30 minutes for presence of any acute reactions and solicited event s, or longer if 
deemed necessary by [CONTACT_093] .Any unsolicited and solicited local (injection site) or systemic AEs 
will be documented by [CONTACT_1758] -site personnel following this observation period. Each participant will 
record solicited local and systemic AEs and body temperature in the participant diary, beginning on the 
evening of the vaccination day and daily for 7 days after vaccination .
Nasosorption samples using synthetic absorptive matrix (SAM) strips , blood samples to assess humoral 
and cellular immune responses , and clinical safety laboratory blood samples (Cohorts 2 and 3 only) will 
be collected. Particip ant safety throughout the study will further be evaluated via physical examinations 
and vital signs .
NUMBER OF PARTICIPANTS
A target of approximately 450 participants will be randomly assigned to different dose levels of 
Ad26.RSV.preF in theAd26/protein preF RSV vaccine or to placebo in 3 cohorts . In Cohort 1, a target of 
approximately 225participants will be randomized , whereas in Cohorts 2 and 3,a target of 125 and 
100participants will be randomized, respectively .
VACCINATION GROUPS AND DUR ATION
The study duration will be approximately 6 months per participant . Participants in Cohort 1 will be 
screened on Day 1 (prevaccination) , whereas participants in Cohorts 2 and 3 will be screened within 
28days before study vaccine administration to analyze clinical safety laboratory parameters before 
vaccination. Thestudy further comprises study vaccination (active or placebo) on Day 1 and a 6-month 
safety and immu nogenicity follow -up period .
If a participant meets any of the contraindications to vaccination at the scheduled time for study  
vaccination on Day 1, enrollment at a later date is permitt ed at the discretion of the PI [INVESTIGATOR_233793] .
Study Vaccine Administration
On Day 1, participants will receive a single I M injection of study vaccine (ie, the Ad26/protein preF RSV 
vaccine or placebo) in the deltoid muscle . The injection will occur at the study site. TheAd26/protein 
preF RSV vaccine is composed of Ad26.RSV.preF (JNJ-64400141) and RSV preF protein 
(JNJ-64213175) . Ad26.RSV.preF will be administered at a dose level ranging from 3.7×109viral particles 
(vp) to 1.6×1011vp, and RSV preF protein at a constant dose level of [ADDRESS_282186] of 0.9% saline.
IMMUNOGENICITY EVALUATIONS
Venous blood samples of approximately 10 and 50 mL will be collected for the determinati on of humoral 
and cellular immune responses, respectively . Nasosorption samples using SAM strips will be collected for 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
9
Status: Approved ,  Date: 16 March 2020immunogenicity assessments including, but not limited to,determination of antigen -specific 
immunoglobulin (IgG and IgA ).
Assay Purpose
Primary and secondary endpoints
Pre-F protein binding antibody (ELISA) Analysis of antibodies binding to RSV F protein in prefusion form
RSV A2 neutralization Analysis of neutralizing antibodies to the A2 strain
IFN- γ (ELISpot) T-cell IFN -γ responses to RSV F protein peptides
Exploratory endpoints
Post-F protein binding antibody (ELISA) Analysis of antibodies binding to RSV F protein in postfusion form
Antigen -specific T -cell immune 
responsesAnalysis of T -cell responses to RSV F protein peptide -stimulated 
PBMCs (including, but not limited to, CD4+/CD8+, IL-2, IFN -γ, 
TNF -α, activation markers and memory) using ICS or CyTOF
RSV strain cross -neutralization Analysis of cross -neutralizing antibodies to B and/or other 
Astrain(s)
Antibody specificity and functional 
characterizationAnalysis of pre-and post -F antibody specificity by [CONTACT_233823], competition ELISA ,and epi[INVESTIGATOR_111050]. 
Functional characterization of antibodies including, but not limited 
to, ADCC, ADCP, avidity, immunoglobulin isotype ,and functional 
VNAs to other respi[INVESTIGATOR_233794], but not limited to, IgA and 
IgGAnalysis of nasal antibodies binding to RSV F protein in prefusion 
and/or postfusion form in nasal samples
Adenovirus neutralization assay Analysis of neutralizing antibodies to Ad26
ADCC = antibody -dependent cell-mediated cytotoxicity; ADCP = antibody -dependent cellular phagocytosis; CD=cluster of 
differentiation; CyTOF = cytometry by [CONTACT_233824]; ICS = intracellular cytokine staining ;IL = interleukin; PBMC = peripheral 
bone mar row cell; TNF = tumor necrosis factor ; VNA = virus neutralization assay .
SAFETY EVALUATIONS
Key safety assessments will include the monitoring of AEs, physical examinations, vital signs, and 
clinical safety laboratory assessments .
AEs and special reporting situations, whether serious or nonserious, that are related to stud y procedures or 
that are related to noninvestigational sponsor products will be reported from the time a signed and dated
informed consent form (ICF) is obtained until the end of the study/early withdrawal .All other unsolicited 
AEs and special reporting situations, whether serious or nonserious, will be reported from the time of 
vaccination until 28 days after vaccination. All AEs and SAEs leading to discontinuation of the study 
vaccination (regardless of the causal relationship ) are to be reported from the moment of vaccination until 
completion of the participant’s last study -related procedure, which may include contact [CONTACT_233825] -up. All other SAEs (regardless of the causal relations hip) are to be reported from the time of 
vaccination until the end of the study/early withdrawal.
Any solicited local (injection site) or systemic AEs occurring during the 30-minute postvaccination 
observation period (or longer if deemed necessary by [CONTACT_093]) will be documented by [CONTACT_10748] -site personnel following this observation period. Solicited AEs collected through a participant diary  
will be recorded from the time of vaccination until 7 days after vaccinati on.
STATISTICAL METHODS
Sample Size Determination
Immunogenicity (Cohort 1)
The primary objective of Cohort 1 is to explore the dose-response relationship of humoral immune 
responses (as measured by [CONTACT_233826] )induced by [CONTACT_233827]26/protein preF RSV 
vaccine .
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
10
Status: Approved ,  Date: 16 March 2020Assum ing:
 10% of exclusions (eg, drop-outs, missing samples, and major protocol deviations impacting 
immunogenicity data)
 a standard deviation on the log 2scale of the preF ELISA of 1.3 on Day 15 and 1.1 on Day 183 for all 
dose levels
 4 dose levels
The l inear model log 2(preF ELISA timepoint ) = GMT preF ELISA Ad26/protein preF RSV vaccine (1x1011vp/150 µg),timepoint + 
slope ×#titration steps provides a standard error for the slope of 0.052 on Day 15 and 0.040 on Day 183
with 50 participants per arm. This is deemed sufficient for this exploratory study.
Safety (Cohorts 1, 2, and 3)
Placebo recipi[INVESTIGATOR_233795].
Theobservation of 0 events (eg,SAEs) is associat ed with 95% confidence that the true event rate is 
below the rates specified in the below table for the considered number of participants .
Sample Size N=25 N=50 N=75
UL 95%  one-sided CI 11.3% 5.8% 3.9%
CI = confidence interval; N = number of participants; UL = upper limit.
The t able below provides the probability of observing at least one AE in a group of the considered sample 
size given several true AErates .
True AE Rate (%)Probability of Observing at Least One AE in N Participants (%)
N=25 N=50 N=75
0.5 12 22 31
1 22 39 53
2.5 47 72 85
10 93 99 100
25 100 100 100
50 100 100 100
N = number of participants.
Analysis Sets
Vaccine assignment will follow the as -treated principle.
The Full Analysis Set(FAS) will include all participants who were randomized and received the study
vaccine, regardless of the occurrence of protocol deviations. All safety and participant information 
analyses will be based on the FA S.
The Per-protocol Immunogenicity (PPI) Setwill include all participants who were randomized and 
received thestudy vaccine , and for whom immunogenicity data areavailable, excluding participants with 
major protocol deviations expecting to impact the immunogenicity outcomes.
The analysis of all immunogenicity endpoints will be based on the PPI [CONTACT_55866]. For key tables, sensitivity 
immunogenicity analyses might also be performed on the FAS.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
11
Status: Approved ,  Date: 16 March 2020Immunogenicity Analyses
No formal statistical testing of immunogenicity data is planned. Immunogenicity data will be analyzed 
descriptively by [CONTACT_233828] . In addition, for a selection of tables, data m aybe pooled over cohorts.
To explore the dose-response relationship between preF ELISA and different dose levels of the
Ad26/protein preF RSV vaccine, a linear regression model will befitted for each timepoint separately, 
using data of the active groups of Cohort 1, with the log -transformed preF ELISA titers at the considered 
timepoint as dependent variable, the number of titration steps as independent variable, and the geometric 
mean titer (GMT) of preF ELISA of the Ad26/protein preF RSV vaccine (1×1011vp/150 µg)at the 
considered timepoint as a fixed intercept.
The linear model log 2(preF ELISA timepoint ) = GMT preF ELISA Ad26/protein preF RSV vaccine (1x1011vp/150 ug),timepoint + 
slope ×#titration steps will initially be fitted for the active groups of Cohort 1 but may be extended in a 
later stage with data of the active groups of Cohorts 2 and 3. A similar model may be fitted as well for 
other assays.
Depending on the model fit, other models (eg,log-linear models or EMAX models) may be explored as 
well.
Safety Analyses
No formal statistical testing of safety data is planned. Safety data will be analyzed descriptively by [CONTACT_233829] . In addition, for a selection of tables, data of Cohorts 2 and 3 may be pooled . All safety  
analyses will be based on the FAS.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
12
Status: Approved ,  Date: 16 March [ZIP_CODE].2. Schema
Figure 1: Schematic Overview of the Study
D = Day.
Note that the scale of the timelines is arbitrary for clarity purposes.
In Cohort 2, ablinded 24-hour (Day 2) postvaccination safety review of the sentinel group of 5 participants will be performed by [CONTACT_978](s) and sponsor team members 
(Step 1). In the absence of any clinical safety concerns, an additional 15 participants will be enrolled (Step 2). After review of the 7 -day (Day 8) postvaccination 
safety data of these 20participants by [CONTACT_16009], the remaining participants in the cohort will be enrolled (Step 3). Based on the review of all available safety data up 
to at least 7 days after vaccination of all participants in Cohort 2 by [CONTACT_16009] (dashed line), the sponsor maydecide to not initiate enrollment of Cohort 3.
The enrollment of Cohort 3 will be conducted similarly to Cohort 2. Steps 1 and 2 w ill be performed with a sentinel group of 4 participants and with 12 participants, 
respectively. After review of the 7 -day (Day 8) postvaccination safety data of these 16 participants by [CONTACT_16009], the remaining participants in the cohort w ill be 
enrolled .

VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
14
Status: Approved ,  Date: 16 March 2020prevaccination ; pre-and post vaccination ; if the early exit visit is within 8 days after vaccination;  blood samples for immunogenicity will only be taken if the early exit visit is at least 
14days after the previous immunogenicity blood draw; ifthe early exit visit iswithin 7 days after vaccination; if the early exit visit is within 28 days after vaccination; at the discretion of the 
investigator (based on health status of the participa nt).
a. Can be electronic (eg, e -mail, text messages) or by [CONTACT_648].
b. An early exitvisit will be conducted for those participants who are unable to continue participation in the study and withdraw from the study before Day 183, but who do not 
withdraw consent. Participants who wish to withdraw consent from participation in the study will be offered an early exit visit (prior to forma l withdrawal of consent).
c. Signing of the ICF should be done before any study -related activity.
d. Prestudy therap iesadministered up to [ADDRESS_282187] be recorded.
e. A physical examination (including height and body weight) will be carried out at screening . At all other visits, an abbreviated, symptom -directed physical examination will be 
performed if deemed necessary by [CONTACT_093].
f. Systolic and diastolic blood pressure (supi[INVESTIGATOR_050]) and heart and respi[INVESTIGATOR_233796] [ADDRESS_282188] in a quiet setting without distractions 
(eg,television, cell phones). Vital signs measurements should be taken before nasal sampling and blood draws , if applicable.
g. Investigator must check for acute illness or body temperature of ≥38.0°C (≥100.4 ºF) at the time of vaccination. In such cases , the participant may be vaccinated up to, and no later 
than, 1 0 days after the scheduled vaccination, or be withdrawn from vaccination at the discretion of the investigator.
h. After vaccination, participants will be closely observed for a minimum of 30 minutes to monitor for the development of any ac ute reactions and s olicited events , or longer if deemed 
necessary by [CONTACT_093]. Any unsolicited and solicited local (injection site) or systemic AEs , and vital signs (heart and respi[INVESTIGATOR_697], systolic and d iastolic bl ood pressure
[supi[INVESTIGATOR_050]] ,and body temperature) will be documented by [CONTACT_1758] -site personnel following this observation period.
i. Participants will be asked to note in the participant diary occurrences of injection site pain/tenderness, erythema, and swelling at the injection site daily. The extent (lar gest diameter) 
of any erythema and swelling should be measured using the supplied ruler and recorded daily. Body temperature (oral route pre ferred) should be measured at approximately the same 
time each day, preferably in the evening, using the supplied th ermometer. If more than one measurement is made on any given day, the highest body temperature of that day will be 
used in the participant diary.
j. AEs and special reporting situations related to study procedures or to noninvestigational sponsor products will be reported from the time a signed and dated ICF is obtained until the 
end of the study/early withdrawal. Allother AEs (unsolicited) and other special reporting situations will be reported from the time of vaccination until 28 days after vaccination.
AllAEs leading to discontinuation ofstudy vaccination (regardless of the causal relationship) are to be reported from the moment of vaccination until completion of the participant’s 
last study -related procedure, which may include contact [INVESTIGATOR_8178] s afety follow -up.
k. SAEs related to study procedures or to noninvestigational sponsor products will be reported from the time a signed and dated ICF is obtained until the end of the study/early 
withdrawal .All SAEs leading to discontinuation of study vaccinat ion (regardless of the causal relationship) are to be reported from the moment of vaccination until completion of 
the participant’s last study -related procedure, which may include contact [CONTACT_160181] -up.All other SAEs (regardless of the causal relat ionship) are to be reported from the time 
of vaccination until the end of the study/early withdrawal .
l. Concomitant therapi[INVESTIGATOR_160134]/antipyretic medications and nonsteroidal anti -
inflammatory drugs, corticosteroids, and antihistaminic must be recorded until 28 days after 
vaccination. All other concomitant therapi[INVESTIGATOR_233797] 10.3, Appendix 3.
m. Participants will be contact[CONTACT_218907] 8 to review the information noted in the participant diary. If the participant diary review is missed, the diary information will be review ed 
during the following visit. The participant diary will be collected at the Day 15 visit.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
16
Status: Approved ,  Date: 16 March 2020a. Can be electronic (eg, e -mail, text messages) or b y phone.
b. An early exitvisit will be conducted for those participants w ho are unable to continue participation in the study and withdraw from the study before Day 183, but who do not 
withdraw consent . Participants who wish to withdraw consent from participation in the study will be offered an early exit visit (prior to formal withdrawal of consent).
c. In addition, the first [ADDRESS_282189] be recorded.
f. A physical examination (including height and body weight) will be carried out at screening. At all other visits, an abb reviated, symptom -directed physical examination will be 
performed if deemed necessary by [CONTACT_093].
g. Systolic and diastolic blood pressure (supi[INVESTIGATOR_050]) and heart and respi[INVESTIGATOR_233796] [ADDRESS_282190] in a quie t setting without distractions 
(eg,television, cell phones). Vital signs measurements should be taken before nasal sampling and blood draws, if applicable.
h. To review inclusion criteri on3and exclusion criteria 2, 8, 9, 10, 11, and [ADDRESS_282191] check for acute illness or body temperature of ≥38.0°C (≥100.4 ºF) at the time of vaccination. In such cases, the participant may be vaccinated up to, and no later 
than, 10 days after the scheduled vaccination, or be withdrawn from vaccination at the discre tion of the investigator.
j. After vaccination, participants will be closely observed for a minimum of 30 minutes to monitor for the development of any ac ute reactions and solicited events , or longer if deemed 
necessary by [CONTACT_093]. Any unsolicited an d solicited local (injection site) or systemic AEs, and vital signs (heart and respi[INVESTIGATOR_697], systolic and d iastolic bl ood pressure
[supi[INVESTIGATOR_050]] ,and body temperature) will be documented by [CONTACT_1758] -site personnel following this observation period.
k. Partici pants will be asked to note in the participant diary occurrences of injection site pain/tenderness, erythema, and swelling at the injection site daily. The extent (largest diameter) 
of any erythema and swelling should be measured using the supplied ruler and recorded daily. Body temperature (oral route preferred) should be measured at approximately the same 
time each day, preferably in the evening, using the supplied thermometer. If more than one measurement is made on any given d ay, the highest body temperature of that day will be 
used in the participa nt diary.
l. AEs and special reporting situations related to study procedures or to noninvestigational sponsor products will be reported from the time a signed and dated ICF is obtained until the 
end of the study/early withdrawal. Allother AEs (unsolicited) and other special reporting situations will be reported from the time of vaccination until 28 days after vaccination.
AllAEs leading to discontinuation of study vaccination (regardless of the causal relationship) are to be reported from the moment of vacc ination until completion of the participant’s 
last study -related procedure, which may include contact [CONTACT_160181] -up.
m. SAEs related to study procedures or to noninvestigational sponsor products will be reported from the time a signed and dated ICF is obtained until the end of the study/early 
withdrawal .All SAEs leading to discontinuation of study vaccination (regardless of the causal relationship) are to be reported from the moment of vaccination until completion of 
the participant’s last study -relate d procedure, which may include contact [CONTACT_160181] -up.All other SAEs (regardless of the causal relationship) are to be reported from the time 
of vaccination until the end of the study/early withdrawal.
n. Concomitant therapi[INVESTIGATOR_160134]/antipyretic medications and nonsteroidal anti
-inflammatory drugs, corticosteroids, and antihistaminic must be recorded until 28 days after 
vaccination. All other concomitant therapi[INVESTIGATOR_233798] w or worsening AEs reported per protocol requirements outlined in 
Section 10.3, Appendix 3.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
17
Status: Approved ,  Date: 16 March [ZIP_CODE].INTRODUCTION
The respi[INVESTIGATOR_227899] ( RSV )vaccine that will be investigated in the current study , the 
Ad26/protein preF RSV vaccine (VAC18193), is a combination of 2vaccine components, 
administered as a single intramuscular (IM) injection:
Ad26.RSV.preF (JNJ-64400141), a replication- incompetent adenovirus seroty pe 26 (Ad26) 
containing a DNA transgene that encodes the prefusion conformation -stabilized F protein 
(preF) derived from the RSV A2 strain.
RSV preF protein (JNJ-64213175), a recombinant preF protein derived from the RSV A2 
strain.
For the most comprehensive nonclinical and clinical information regarding the Ad26/protein 
preF RSV vaccine , refer to the latest version sof the Investigator ’s Brochure s(IBs)for
Ad26.RSV.preF and RSV preF protein .8,9
The term "study  vaccine "used throughout the protocol refers to the Ad26/protein preF RSV 
vaccine or placebo .
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
2.1. Study Rationale
The aim of this dose-ranging study  is to determine the safet y and immunogenicity  of different 
dose levels of Ad26.RSV.preF in the Ad26/protein preF RSV vaccine to support the refinement 
of the acceptance criteria for drug product release and stability  by [CONTACT_233830] y (for the upper release limit) and immunogenicity  (for the lower 
release limit) .
2.2. Background
RSV is an important cause of serious respi[INVESTIGATOR_233799] ≥[ADDRESS_282192] numbers on the burden of RSV disease in adults aged ≥60years arelimited.
Inlong-term care facilities, RSV is estimated to infect 5% to 10% of the residents per year with 
significant rates of pneumonia (10% -20%) and death (2%-5%) as a consequence.6In the United 
States, approximately  177,000 hospi[INVESTIGATOR_233800]  10,000 to 14,000 deaths 
per year are due to severe RSV infections in adults aged ≥[ADDRESS_282193] RSV in older adults could be 
attributed to an age-related decline in interferon (IFN) -γproduction by [CONTACT_233831], a reduced ratio of cluster of differentiation ( CD)8+to CD4+Tcells, and 
reduced numbers of circulating RSV -specific CD8+memory  T cells.4,12,13High levels of serum 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
18
Status: Approved ,  Date: 16 March 2020neutralizing antibody  are associated with less severe infections in older adults.19
TheAd26.RSV.preF vaccine component being evaluated in this protocol is based on the AdVac®
platform which has been shown to promote a strong antibody  response as well as cellular
responses.2,3,10,[ADDRESS_282194] higher virus 
neutralizing titers ( VNTs) than immunization with Ad26.RSV.preF alone. In RSV pre-exposed 
nonhuman primates (NHPs ), the combination of the human dose of both Ad26.RSV.preF and 
RSV preF protein induced high VNTs. Due to the high VNT response induced by [CONTACT_233832]26.RSV.preF alone, there was no significant difference observed with the VNT induced by 
[CONTACT_233833]26.RSV.preF. In both RSV pre-exposed mice and 
NHP s, Ad26.RSV.preF induced Th1- skewed cellular responses, in combination with RSV preF 
protein and alone , as suggested by [CONTACT_20129]-γ enzyme -linked immunospot (ELISpot) assay s and
intracellular cytokine staining (ICS) . In contrast, RSV preF protein alone induced only low 
cellular responses. In RSV pre-exposed NHPs, immunization with the combination of 
Ad26.RSV.preF and RSV preF protein boosted pre-existing neutr alizing antibody  responses
against a panel of different RSV A and B strains, including recent clinical isolates. VNTs against 
RSV A strains were monitored for [ADDRESS_282195] protection in 100% of animals after RSV A2 intranasal 
challenge. Due to the high efficacy  of Ad26.RSV.preF alone in the naïve cotton rat model even 
at lowest doses that elicited an immune response , the value of theaddition ofRSV preF protein 
for protection of lower respi[INVESTIGATOR_233801] d. However, upper respi[INVESTIGATOR_233802]26.RSV.preF.
2.2.2. Ad26.RSV.preF and RSV preF Protein Clinical Studies
At the time of protocol writing, 2Phase 1 studies (VAC18193RSV1003 and 
VAC 18193RSV1005) and 2Phase 2a studies (VAC18193RSV2002 and VAC18193RSV2003) 
with Ad26.RSV.preF have been completed. Three Phase 1/2a studies (VAC18193RSV1004, 
VAC18194RSV2001, and VAC18194RSV2002) and onePhase 2b study  (VAC18193RSV2001) 
are ongoing (Table 1).
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
19
Status: Approved ,  Date: 16 March 2020Table 1: Overview of Clinical Studies With Ad26.RSV.preF
Study Identifier
Study StatusClinical 
PhaseVaccine N Study Population
Senior Program
VAC18193RSV1003
Com pleted1 Ad26.RSV.preF 72 Adult participants aged 60 years and older in 
stable health
VAC18193RSV1005
Com pleted *1 Ad26.RSV.preF 24 Adult participants aged 18 years and older in 
stable health (including 3 participants aged 
>65years)
VAC18193RSV2002
Com pleted2a Ad26.RSV.preF 63 Healthy adult participants aged 18 to 50 years
VAC18193RSV2003
Com pleted2a Ad26.RSV.preF 180 Adult participants aged 60 years and older in 
stable health
VAC18193RSV1004
Ongoing1/2a Ad26.RSV.preF/
RSV preF protein 667 Adult participants aged 60 years and older in 
stable health
VAC18193RSV2001
Ongoing2b Ad26.RSV.preF/
RSV preF protein 5,800 Adult participants aged 65 years and older with 
and without comorbidities 
Junior Program
VAC18194RSV2001
Ongoing1/2a Ad26.RSV.preF 12 adults
36 toddlersHealthy adult participants aged 18 to 50 years 
and healthy RSV -seropositive toddlers aged 
12to24months
VAC18194RSV2002
Ongoing1/2a Ad26.RSV.preF 48 toddlers Healthy RSV -seronegative toddlers aged 
12to24months
* Clinical study report w riting in progress .
Clinical studies are ordered to align with the order in the clinical development plan.
N = actual number of participants (for completed studies) or planned number of participants (for ongoing studies).
Study VAC18193RSV1003 is a completed single -center, randomized, placebo- controlled, 
double -blind, first-in-human Phase 1study for theAd26.RSV.preF vaccine, and demonstrated 
that Ad26.RSV.preF was safe and well tolerated at 2doses (5×1010viral particles [vp]and 
1×1011vp) and can elicit durable (up to 2 years) humoral and cellular immune responses against 
RSV . The data suggested a trend towards higher humoral responses after vaccination with the 
higher dose level of Ad26.RSV.preF compared with the lower dose level.
After the safet y, tolerability ,and immunogenicity  profile of Ad26.RSV.preF was first established 
in study  VAC18193R SV1003, study VAC18193RSV2002, a completed single -center, 
randomized, placebo- controlled, double -blind exploratory  Phase 2a human challenge study ,was 
conducted in participants aged 18to 50yearsto evaluate the proph ylactic efficacy  of a single 
immunization of Ad26.RSV.preF against RSV infection in a virus challenge model. There was a 
statistically  significant reduction in the viral load as measured by [CONTACT_233834]
(VL-AUC ) in the Ad26.RSV.preF group compared with placebo , and Ad26.RSV.preF 
vaccination was associated with lower peak viral loads (by [CONTACT_233835] ), lower VL -AUC (by [CONTACT_233836]) ,and a substantial reduction 
in the median area under the curve of the total clinical symptom score. Immunization with 
Ad26.RSV.preF substantially  reduced the proportion of participants infected by [CONTACT_233837]. Symptoms of RSV infection and RSV viral load by [CONTACT_233838] y reduced in Ad26.R SV.preF vaccinated participants with breakthrough RSV infection 
compared with placebo. Vaccination with Ad26.RSV.preF induced favorable humoral immune 
responses compared with placebo as measured prior to RSV challenge.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
20
Status: Approved ,  Date: 16 March 2020With the availability  of clinical trial material (CTM) for RSV preF protein and taking the results 
of the VAC18193RSV1003 and VAC18193RSV2002 studies into account , the following clinical 
studies with Ad26.RSV.preF and RSV preF protein were initiated and are ongoing:
Study  VAC18193RSV1004 is amulticenter , randomized, double -blind, placebo- controlled
Phase 1/2a regimen selection study  in 667 participants aged ≥60years in stable health to evaluate
the safet y and immunogenicity  of Ad26.RSV.preF alone, of combinations of Ad26.RSV.preF 
and RSV preF protein, and of separate administration of Ad26.RSV.preF and RSV preF protein.
A significant increase in humoral immune responses including virus neutralization assay s 
(VNAs )and preF antibody  titers was observed in the groups combining Ad26.RSV.preF and
RSV preF protein compared with Ad26.RSV.preF alone. No relevant differences between the 
combination groups and Ad26.RSV.preF alone were noted for cellular immune responses 
measured at the time of primary  analysis. All regimens had acceptable safety  and reactogenicit y
profiles, which were similar across groups. Available safet y data support that this vaccine is safe 
and has an acceptable reactogenicity profile.
Study  VAC18193RSV2001 is a multicenter, randomized, double -blind, placebo- controlled
Phase 2b proof -of-concept study  in approximately  5,800 participants aged ≥65years with and 
without comorbidities to confirm the potential for efficacy  of the Ad26/protein preF RSV
vaccine and to assess [ADDRESS_282196] disease.
2.3. Benefit -riskAssessment
Below, the known and potential benefits and risks of VAC18193 (JNJ-64400141/JNJ -64213175)
are discussed. More detailed information about the known and expected benefits and risks of the 
Ad26/protein preF RSV vaccine may be found in the IBsforAd26.RSV.preF8and RSV preF 
protein9.
2.3.1. Know n Benefits
The clinical benefits of the Ad26/protein preF R SV vaccine have yet to be established.
2.3.2. Potential Benefits
The Ad26/protein preF RSV vaccine isunder development for prophy laxis of RSV, however ,
vaccine efficacy  has not yet been evaluated. Based on preliminary  immunogenicity  data, there 
could be a potent ial benefit from RSV vaccination in terms of immune response: vaccination 
could raise an immune response which might confer additional protection against a future RSV 
infection (Section 2.2.2 ).The individual benefit from vaccination for the participants at the 
current development stage is not known.
Participants may benefit from clinical testing and physical examination; others may benefit from 
the knowledge that they  may  aid in the development of an RSV vaccine.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
21
Status: Approved ,  Date: [ADDRESS_282197] the potential to cause adverse experiences. To date, limited clinical data with 
the Ad26/protein preF RSV vaccine showed an acceptable safet yand reactogenicit yprofile
(Section 2.2.2 ).
2.3.4. Potential Risks
The following potential risks for the Ad26/protein preF RSV vaccine will be monitored during 
thestudy :
Risks Related to Vaccination
In general, IM injection may cause local itching, warmth, pain, tenderness, erythema/redness, 
induration/swelling, arm discomfort, or bruising of the skin at vaccine injection sites. 
Participants may exhibit general signs and symptoms associated with administration of a 
vaccine, or vaccination with placebo, including fever, chills, rash, myalgia, nausea/vomiting, 
headache, dizziness , arthralgia, general itching, and fatigue. These side effects will be monitored 
but are generall yshort -term and do not require treatment.
Syncope can occur in association with administration of injectable vaccines. Syncope can be 
accompanied by [CONTACT_130361]. Procedures should be in place to avoid injury from falling. Ifsyncope 
develops, participants should be observed until the symptoms resolve. Fear of injection might 
lead to fainting and fast breathing.
Participants may have an allergic reaction to the vaccination. An allergic reaction may cause a 
rash, urticaria, or even anaphy laxis. Severe reactions arerare. Participants with a known allergy 
or history  of anaph ylaxis or other serious adverse reactions to vaccines or vaccine components 
(including any of the constituents of the study  vaccine) will be excluded from the study . Study 
sites should have medica l treatment available in case of severe allergic reactions following 
vaccine administration.
Risks Related to Adenoviral -vectored Vaccines
Safety  data available from 23 clinical studies in 3,694 adults vaccinated with Ad26 -vectored 
vaccine candidates, in which Ad26 with different inserts has been evaluated at dose levels 
ranging from 1×109to 1×1011vp, indicate that no safet y concerns would be anticipated from 
vaccination with Ad26.RSV.preF at dose levels up to and including 1×1011vp.[ADDRESS_282198] consisted of 
mild to moderate adverse events (AEs), including local injection site reactions (most frequently 
injection site pain), and malaise, fatigue, headache, and myalgia . Atrend towards an increase in 
the incidence of injection site pain and arthralgia, chills, fatigue, headache, malaise, my algia, and 
nausea with anincrease in Ad26 dose level was observed .There was no clear trend in the 
frequency  of unsolicited AEs with increasing the Ad26 dose level .Transient decreases in 
neutrophil counts have been associated with adenovirus -based vaccines, and decrease in 
hemog lobin from baseline was the most frequent laboratory  abnormality .1
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
22
Status: Approved ,  Date: [ADDRESS_282199] shown an acceptable safety  and 
reactogenicity profile.
Risks from Collection of Nasosorption Samples
Nasosorption sampling is more comfortable and less invasive than using a conventional swab
(which may  cause nose bleeds).
Risks from Blood Draws
As with all clinical studies requiring blood sampling, there are risks associated with venipuncture 
and multiple blood sample collection. Blood drawing may cause pain, tenderness, bruising, 
bleeding, dizziness, vaso-vagal response, syncope, and, rarel y, infection at the site where the 
blood is taken. The total blood volume to be collected is considered to be an acceptable amount of 
blood over this time period from the population in this study  (Section 4.2.1 ).Participants with 
contraindications to IM injections and blood draws (eg, bleedi ng disorders) will be excluded.
Participants with Immunosuppression/Reduced Immune Response
Participants with abnormal function of the immune system will be excluded from the study . 
Limited evidence indicates that inactivated vaccines (or nonreplicating viral vaccines) generall y 
have the same safet y profile in immunocompromised patients as in immunocompetent 
individuals. However, the magnitude, breadth, and persistence of the immune response to 
vaccination may  be reduced or absent in immunocompromised per sons.
Concomitant Vaccination
Concomitant vaccination might have an influence on both the safety  profile and immunogenicity 
ofAd26.RSV.preF and/or RSV preF protein. L ikewise, Ad26.RSV.preF and/or RSV preF protein
might have an influence on both the safet yprofile and immunogenicity of any concomitant 
vaccination. As a result, licensed live attenuated vaccines should be given at least 28 day s before 
or after vaccination . Other licensed (not live) vaccines (eg, influenza, tetanus, hepatitis A, 
hepatitis B, rabies) should be given at least 14 daysbefore or after vaccination to avoid potential 
confusion of adverse reactions and potential immune interference. If a vaccine is indicated in a 
postexposure setting (eg, rabies or tetanus), it must take priorit y over the study  vaccine .
Reproductive Risks and Pregnancy
The effect of Ad26.RSV.preF and RSV preF protein on a fetus or nursing baby [CONTACT_111175]. 
Female participants may therefore only participate if they are postmenopausal (defined as no 
menses for 12 months without an alternative medical cause) and not intending to conceive by 
[CONTACT_130362]. Women who have had hysterectomies are also eligible for the study . Because the 
effect on sperm is unknown, male participants must inform the study -site personnel if their 
partner becomes pregnant during the study . Follow -up information regarding the outcome of the 
pregnancy  and any  postnatal sequelae in the infant will be required.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
23
Status: Approved ,  Date: 16 March 2020Unknown Risks 
There may be other risks that are not known. If any significant new risks are identified, the 
principal investigator (PI)and participants will be informed.
2.3.5. Overall Benefit -risk A ssessment
Based on the available data and proposed safet y measures, the overall benefit -risk assessment for 
this clinical study  is considered acceptable fo r the following reasons:
The dose level of 1×1011vp for Ad26.RSV.preF and 150µgfor RSV preF protein 
(administered in all 3cohorts) was selected from the primary  analysis of Cohort 2 in study 
VAC18193RSV1004 and is currently  under further evaluation in studies
VAC18193RSV1004 and VAC18193RSV2001 (Section 4.1). Available safet y data of study
VAC18193RSV1004 support that this vaccine is safe and has an acceptable reactogenicit y
profile at a dose level up to 1×1011vp(Section 2.2.2 ).As no data areavailable for higher 
dose levels, adequate safety  measures will be taken to minimize the risk to participants (see 
below).
Only  participants who meet all inclusion criteria (Section 5.1) and none of the exclusion 
criteria (Section 5.2) will be allowed to participate in this study . The selection criteria 
include adequate provisions to minimize the risk and protect the well -being of participants in 
the study .
Safety  (includin g the recording of AEs, physical examinations, vital signs, and clinical 
safet y laboratory  assessments) will be closel y monitored throughout the study:
In general, safet y evaluations will be performed at scheduled visits during the study , as 
indicated in the Schedule of Activities (Section 1.3).
After vaccination, participants will remain at the study  site for a minimum of 
30minutes, or longer if deem ed necessary  by [CONTACT_093], and will be closel y 
observed by [CONTACT_3449]-site personnel . Necessary  emergency  equipment and medications 
must be available at the study  site to treat severe allergic reactions. Participants will use 
a participant diary to document solicited local and systemic symptoms. Details are 
provided in Section s8.2and 8.3.
The investigator or the designee will document unsolicited AEs as indicate d in
Section 8.3.1 .
After vaccination, participants will enter a 6-month safety  and immunogenicit y 
follow -up period. All AEs, serious adverse events (SAEs), and clinically  significant 
laboratory  abnormalities (including those persisting at the end of the study /early 
withdrawal )will be followed by [CONTACT_233839] a 
clinically  stable endpoint is reached, or until theparticipant has been deemed lost to 
follow -up after demonstration of due diligence of follow -up efforts. An early  exitvisit 
will be conducted for those participants who are unable to continue participation in the 
study  and withdraw from the study  before Day 183, but who do not withdraw consent.
Participants who wish to withdraw consent from participation in the study  will be 
offered a nearly exitvisit (prior to formal withdrawal of consent) (Section 7.4).
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
24
Status: Approved ,  Date: 16 March 2020Several safet y measures are included in this protocol to minimize the potential risk to 
participants, including the following:
An internal Data Review Committee (DRC) will be commissioned for this study 
(Section 9.6). Inaddition to the planned review of postvaccination safet y data of 
participants in Cohorts [ADDRESS_282200] one of the study  
vaccination pausing rules has been met and/or ifthe participant’s safety  may be 
threatened.
There are prespecified rules that would result in pausing of further vaccination of 
participants if predefined conditions occur, preventing exposure of new participants to 
study  vaccine until the DRC reviews all available safet y data and subsequent 
communication between the sponsor and the PI(s) takes place (Section 7.3). When a
first DRC meeting has been triggered by [CONTACT_172719] a given study vaccination 
pausing rule, the DRC will convene thereafter for each additional participant meeting 
that pausing rule. Possible actions upon review include, but are not limited to,study 
suspension, study  adaptation, or discontinuation of further vaccination.
In Cohort 2, a sentinel group of 5 participants will be enrolled before enrolling 
additional participants (Step 1)(Section 4.1). In the absence of any clinical safet y 
concerns upon a blinded 24 -hour postvaccination safet y review, an additional 
15participan ts will be enrolled (Step 2). After review of the 7-day (Day  8) 
postvaccination safet y data of these20participants by [CONTACT_16009], the remaining 
participants will be enrolled (Step 3) .
The enrollment of Cohort 3 will be conducted similarly  to Cohort 2. Steps 1 and 2 will 
be performed with a sentinel group of 4 participants and with 12 participants, 
respectivel y, both enrolled in a 1:2:1 ratio. After review of the 7-day (Day 8) 
postvaccination safety  data of these 16 participants by [CONTACT_16009], the remaining 
participants in the cohort will be randomized in a 1:2:1 ratio.
Cohorts 2 and 3 will be enrolled in a staggered manner (Section 4.1). Based on the 
review of all available safet y data up to at least 7 days after vaccination of all 
participants in Cohort 2 by [CONTACT_16009], the sponsor may decide to not initiate enrollment 
of Coho rt 3.
Contraindications to vaccination are included in Section 7.2.
Taking into account the measures taken to minimize risk to participants of this study, the 
potential risks identified in association with the Ad26/protein preF RSV vaccine are justified by 
[CONTACT_233840].
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
25
Status: Approved ,  Date: 16 March [ZIP_CODE].OBJECTIVE S ANDENDPOINTS
Objectives Endpoints
Cohort 1
Primary
 To explore the dose-response relationship of 
humoral immune responses induced by 
[CONTACT_233820]26 .RSV. preF-
based vaccine Antibody titers to RSV preF protein using 
preF enzyme -linked immunosorbent assay 
(ELISA ) at 14 days after vaccination
Secondary
 To explore the dose-response relationship of 
humoral and cellular immune responses 
induced by [CONTACT_233821]26 .RSV. preF- based vaccine Antibody titers to RSV preF protein using 
preF ELISA at 3 and 6 months after 
vaccination
 RSV A2 neutralizing antibody levels at 
14days and 3 and 6 months after 
vaccination
 IFN-γ ELISpot assay at 14 days and 3 and 
6months after vaccination
 To assess the safety and reactogenicity of 
different dose levels of theAd26 .RSV. preF-
based vaccine SAEs from the tim e of vaccination until the 
end of the study
 Solicited local and systemic AEs from the 
time of vaccination until 7days after 
vaccination
 Unsolicited AEs from the time of 
vaccination until 28 days after vaccination
Exploratory
 To explore additional vaccine -elicited immune 
responsesAssays that may be used include, but are not 
limited to:
 Post-Fprotein binding antibodies (ELISA)
 Antigen-specific T- cell immune responses
 RSV cross -neutralization of B and/or other 
A strain(s)
 Anti- F protein antibody specificity 
characterization
 Analysis of immunoglobulin (Ig)A and/or 
IgG antibodies binding to RSV F protein in 
prefusion and/or postfusion form in nasal 
samples
 Analysis of neutralizing antibodies to Ad26
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
26
Status: Approved ,  Date: 16 March 2020Refer to Section 8for evaluations related to endpoints.
HYPOTHESIS
No formal statistical testing of safet y orimmunogenicity data is planned; data will be analy zed 
descriptivel y.Objectives Endpoints
Cohorts 2 and 3
Primary
 To assess the safety and reactogenicity of 
different dose levels of theAd26 .RSV. preF-
based vaccine Solicited local and systemic AEs from the 
time of vaccination until 7 days after 
vaccination
 Unsolicited AEs from the time of 
vaccination until 28 days after vaccination
Secondary
To assess the humoral and cellular immune 
responses induced by [CONTACT_233822]26 .RSV. preF- based vaccine Antibody titers to RSV preF protein using 
preF ELISA at 14 days and 3 and 6months 
after vaccination
 RSV A2 neutralizing antibody levels at 
14days and 3 and 6 months after 
vaccination
 IFN-γ ELISpot assay at 14 days and 3 and 
6months after vaccination
To assess the safety of different dose levels of 
theAd26 .RSV. preF- based vaccine SAEs from the tim e of vaccination until the 
end of the study
Exploratory
 To explore additional vaccine -elicited immune 
responsesAssays that may be used include, but are not 
limited to:
 Post-Fprotein binding antibodies (ELISA)
 Antigen-specific T- cell immune responses
 RSV cross -neutralization of B and/or other 
A strain(s)
 Anti- F protein antibody specificity 
characterization
 Analysis of IgA and/or IgG antibodies 
binding to RSV F protein in prefusion 
and/or postfusion form in nasal samples
 Analysis of neutralizing antibodies to Ad26
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
27
Status: Approved ,  Date: 16 March [ZIP_CODE].STUDY DESIGN
4.1. Over allDesign
This is a randomized, double -blind, placebo- controlled ,multicenter, interventional Phase 2a
study in male and female adults aged ≥60 years who are in stable health, to explore the 
dose-response relationship, safety , and immunogenicity  of a range of dose levels of the
Ad26.RSV .preF -based vaccine .A target of approximately  450 participants will be randoml y 
assigned to dif ferent dose levels of Ad26.RSV .preF in the Ad26/protein preF RSV  vaccine or to 
placebo in 3 cohorts ( Table 2).Thestudy  vaccine will be administered asa single IM injection.
Table 2: Overview of the Cohorts, Groups, and Targeted Number of Participants
Cohort Group N Day 1 (Vaccination)
1(dose -down) 1 50 Ad26.RSV.preF 1×1011vp + RSV preF protein 150 μg
2 50 Ad26.RSV.preF 3.3×1010vp + RSV preF protein 150 μg
3 50 Ad26.RSV.preF 1.1×1010vp + RSV preF protein 150 μg
4 50 Ad26.RSV.preF 3.7×109vp + RSV preF protein 150 μg
5 25 Placebo 
2(dose -up) 6 50 Ad26.RSV.preF 1×1011vp + RSV preF protein 150 μg
7 50 Ad26.RSV.preF 1.3×1011vp + RSV preF protein 150 μg
8 25 Placebo
3(dose -up) 9 25 Ad26.RSV.preF 1×1011vp + RSV preF protein 150 μg
10 50 Ad26.RSV.preF 1.6×1011vp + RSV preF protein 150 μg
11 25 Placebo
N = number of participants.
The study  duration will be approximately  6 months per participant . Participants in Cohort 1 will 
be screened on Day 1 (prevaccination) , whereas participants in Cohorts 2 and 3 will be screened 
within 28days before study  vaccine administration to analy ze clinical safet y laboratory 
parameters before vaccination. (Section 1.3).Thestudy  further comprises study  vaccination 
(active or placebo) on Day [ADDRESS_282201] participant’s last visit (Section 4.4).
In the dose-down cohort (Cohort 1), a target of approximately  225participants will be 
randomized inparallel ina 2:2:2:2:1 ratio to5 groups (Table 2). Participants in Groups 1 to 4 
will receive different dose levels of Ad26.RSV.preF (ranging from 1×1011vp to 3.7×109vp) and 
a constant dose level of RSV preF protein (150 µg)(Section 4.3). Participants in Group 5 will 
receive placebo.
In the dose -upCohort 2, a target of approximately 125participants will be randomized in parallel
in a 2:2:1 ratio to3groups (Table 2). Participants in Groups 6and 8 will receive 1×1011vp 
Ad26.RSV.preF/[ADDRESS_282202] ively , while participants in 
Group 7will receive 1.3×1011vp Ad26.RSV.preF/150 µg RSV preF protein.
Inthe dose -up Cohort 3, a target of approximately 100 p articipants will be randomized in parallel 
in a 1:2:1 ratio to3 groups. Participants in Groups 9 and 11 w ill receive 1×1011vp 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
28
Status: Approved ,  Date: 16 March 2020Ad26.RSV.preF/150 µg RSV preF protein and placebo, respectivel y, while participants in 
Group 10will receive 1.6×1011vp Ad26.RSV.preF/150 µg RSV preF protein (Section 4.3).
Cohorts 1 and 2 may be enrolled in parallel, whereas Cohorts 2 and 3 will be enrolled in a 
staggered manner (Figure 1).A study  site will not simultaneously  enroll participants in more 
than onecohor t.Cohort enrollment to each study sitewill be controlled via the interactive web 
response s ystem ( IWRS ).
Initiall y, a sentinel group of 5participants will be enrolled in Cohort 2 in a 2:2:1 ratio to 
Groups 6to 8, respectively , before enrolling additional participants (Step 1). A blinded 24 -hour 
postvaccination safet y review will be performed by [CONTACT_978](s) and sponsor team members (ie, at 
least thestudy  responsible physician [SRP]/study  responsible scientist [SRS]) . Inthe absence of 
any clinical safet y concerns , anadditional 15participants will be enrolled in a2:2:1 ratio 
(Step 2). After review of the 7-day(Day  8)postvaccination safety data of these 20participants
by [CONTACT_16009], the remaining participants in the cohort will be randomized in a 2:2:1 ratio (Step 3).
When all participants in Cohort [ADDRESS_282203] 7days after vaccination of all participants in the
cohort will be reviewed by  [CONTACT_16009]. Based on this review, the sponsor may decide to notinitiate 
enrollment of Cohort 3.
The enrollment of Cohort 3 will be conducted similarly  to Coho rt 2. Steps 1 and 2 will be 
performed with a sentinel group of 4 participants and with 12 participants, respectivel y, both 
enrolled in a 1:2:1 ratio. After review of the 7-day (Day 8) postvaccination safet y data of these 
16 participants by [CONTACT_16009], the remaining participants in the cohort will be randomized in a 
1:2:1 ratio.
Theplanned primary  and final analysesof all cohorts are detailed in Section 9.5. The primary  
analyses of Cohorts 2 and 3 will be combined.
After vaccination with study  vaccine on Day 1, participants will remain under observation at the 
study  site for a minimum of 30 minutes for presence of any acute reactions and solicited event s, 
or longer if deemed necessary  by [CONTACT_093] .Any unsolicited and solicited local (injection 
site) or systemic AEs will be documented by [CONTACT_1758] -site personnel following this observation 
period. Participants will be given a thermometer, ruler, and a daily  assessment (participant) diary 
with instructions for the proper recording of events. Each participant will record solicited local
and systemic AEs and body  temperature in the participant diary, beginning on the evening of the 
vaccination day and daily for [ADDRESS_282204] and review participant 
diary information and confirm the entries at the next visit.
The reporting periods of AEs, SAEs, and special reporting situations are detailed in Section 8.3. 
Reporting periods for concomitant therap y are outlined in Section 6.5.
Nasosorption samples using synthetic absorptive matrix (SAM) strips will be collected on Day 1 
(prevaccination) and at 14 days and 3 and 6 months after vacci nation (Section 8.1). Blood 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
29
Status: Approved ,  Date: 16 March 2020samples to assess humoral and cellular immune responses will be collected on Day 1 
(prevaccination) and at 14days and 3 and 6 months after vaccination (Section 8.1). Clinical 
safety laboratory  blood samples (Cohorts 2 and 3 only ) will be collected at the screening visit, on 
Day 1 (prevaccination), and at 7 days after vaccination (or at the early exitvisit if this visit is 
within 8days after vaccination and the participant discontinues the study  without withdrawing 
consent) (Section 8.2.3 ). Particip ant safet y throughout the study  will further be evaluated via 
physical examinations and vital signs (Section s 8.2.1 and 8.2.2 , respectively ).
If a participant meets any of the contraindications to vaccination at the scheduled time for study 
vaccination on Day 1, enrollment at a later date is permitt ed at the discretion of the PI [INVESTIGATOR_233803] (Section 7.2).Prior to vaccination on Day  1, arecheck of a selection 
ofinclusion and exclusion criteria will be performed for participants in Cohorts 2 and 3only. 
Participants who fail this recheck may be enrolled at a later date at the discretion of the PI [INVESTIGATOR_233804]. Criteria for participant discontinuation/withdrawal from the 
study , together with the respective actions that must be undertaken, are described in Section 7.
An internal DRC will be commissioned for this study . Refer to Section 9.6for details.
A diagram of the stud y design is provided in Section 1.2.
4.2. Scientific Rati onale for Study  Design
Blinding, Control, Vaccination Groups
A placebo control will be used to establish the frequency  and magnitude of changes in clinical 
endpoints that may occur in the absence of active vaccine . Randomization will be used to 
minimize bias in the assignment of participants to groups, to increase the likelihood that known 
and unknown participant attributes (eg,demographic and baseline characteristics) are evenl y 
balanced across groups, and to enhance the validity  of statistical comparisons across groups. 
Blinded vaccine will be used to reduce potential bias during data collection and evaluation of 
clinical endpoints.
Vaccine Component Selection
The rationale behind the selection of Ad26.RSV.preF and RSV preF protein is described in 
Section 2.2.
Dose Level Selection
The rationale behind the dose level selection for Ad26.RSV.preF and RSV preF protein is 
described in Section 4.3.
Staggered Cohort Enrollment 
and Stepwise Approach
This is the first time that healthy  participants will be vaccinated with Ad26.RSV.preF at a dose 
level of 1.3×1011vpor 1.6×1011vp. Therefore, Cohorts [ADDRESS_282205] 7 days after vaccination of all 
participants in Cohort 2 by [CONTACT_233841] 3. Based on this 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
30
Status: Approved ,  Date: [ADDRESS_282206] of the
[LOCATION_002] Department of Health and Human Services Office for Human Research Protections
and Food and Drug Administration ( FDA )guidelines.17,18
4.3. Justification for Dose Level
The dose level of 1×1011vp for Ad26.RSV.preF and150µgfor RSV preF protein (administered 
in all 3cohorts) was selected from the primary  analysis of Cohort 2 in study 
VAC18193RSV1004 and is currently  under further evaluation in studies VAC18193RSV1004
and VAC18193RSV2001 (Section 2.2.2 ).
The lower dose levels for Ad26.RSV.preF in Cohort 1 of the current study  were selected based 
on the assumption that half-log intervals in dose response are biologically  meaningful for 
vaccines .
There arecurrentl y no safety  data available of Ad26.RSV.preF at a dose level above 1×1011vp. 
Two higher dose levels of Ad26.RSV.preF ( ie, 1.3×1011vp [Cohort 2] and 1.6×1011vp 
[Cohort 3]) will therefore be assessed inthis study .An increase of 0.3×1011vp per dose level 
could lead to a potential increase of target fill concentration of approximately 15% .
In all cohorts, the dose level of RSV preF protein will be kept constant (150 µg) . This dose level 
has been tested in other (ongoing) clinical studies (Section 2.2.2 ).
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
31
Status: Approved ,  Date: [ADDRESS_282207] completed the study  if he or shehas completed 
assessments at the Day  183 visit.
5.STUDY POPULA TION
Screening for eligible participants will be performed prevaccination on Day 1  (Cohort 1) or 
within 28days before study  vaccine administration (Cohorts 2 and 3).Refer to Section 5.4for 
conditions under which the repeat of an y screening procedures are allowed.
The inclusion and exclusion criteria for enrolling participants in this study are described below . 
If there is a question about thesecriteria, the investigator must consult with the appropriate 
sponsor representative and resolve any  issues before enrolling a participant in the study . Waivers 
are not allowed.
Investigators should ensure that all study  enrollment criteria have been met at screening. If a 
participant ’s clinical status changes (including any available laboratory results or receipt of 
additional medical records) after screening but before the time of vaccination such that he or she 
no longer meets all eligibility  criteria, then the participant should be excluded from participation 
in the study .
For a discussion of the statistical considerations of participant selection, refer to Section 9.2.
5.1. Inclusion Criteria
Each potential participant must satisfy  all of the following criteria to be enrolled in the study :
1. Sign an informed consent form (ICF) indicating that he or she understands the purpose, 
procedures, and potential risks and benefits of the study , is willing to participate in the 
study  and attend all scheduled visits, and is willing and able to comply  with all study  
procedures and adhere to the lifesty le restrictions specified in this protocol .
2. Male or female , aged ≥60 y ears on the day  of signing the ICF .
3. In the investigator ’s clinical judgment, participants must be either in good or stable 
health. Participants may have underl ying illnesses such as hypertension, type 2 diabetes 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
32
Status: Approved ,  Date: 16 March 2020mellitus, hyperlipoproteinemia, or hypothy roidism, as long as their signs and symptoms 
are stable and medically  controlled in the judgment of the investigator . Participants will 
be included on the basis of medical history  and of physical examination and vital signs 
performed at screening (all cohorts), and of physical examination and/or vital signs 
performed prevaccination on Day  1 (Cohorts 2 and 3).
Note : Retesting of abnormal vital sign values that may lead to exclusion, or due to 
equipment malfunction, is allowed once without prior approval fr om the sponsor .
4. A woman must be postmenopausal (defined as no menses for 12 months without an 
alternative medical cause) and not intending to conceive b y any methods.
Note : Women who have had hysterectomies arealso eligible for the study.
5. Agree to not donate blood from the time of vaccination until [ADDRESS_282208] a bod y mass index (BMI) <40 kg/m².
7. Be willing to provide verifiable identification and have means to be contact[CONTACT_233842] y.
For participants in Cohorts 2 and 3 only:
10. Be healthy  on the basis of clinical laboratory  tests performed at screening. If the results 
of the laboratory  screening tests are outside the central laboratory  normal reference 
ranges and additionall y within the limits of toxicity  Grade 2 according to the United 
States FDA toxicity  tables (ie, for tests in the FDA table) (Section 10.2, Appendix 2), 
the partic ipant may be included only if the investigator judges the abnormalities or 
deviations from normal to be not clinically  significant and appropriate and reasonable 
for the population under study . This determination must be recorded in the participant’s 
sourc e documents and initialed by  [CONTACT_093].
Note : Screening laboratory tests are to be done within 28 days before vaccination. If the 
results of the laboratory screening tests are outside the central laboratory normal 
reference ranges and deemed clinically significant by [CONTACT_093], repeat of 
screening laboratory tests will be permitted once using an unscheduled visit during the 
screening period to assess eligibility.
5.2. Exclusion Criteria
Any potential participant who meets any of the following criteria will be excluded from 
participating in the stud y:
1. Has a contraindication to I M injections and blood draws (eg, bleeding disorders).
2. Has a clinicall y significant acute illness (this does not include minor illnesses such as 
diarrhea or mild upper respi[INVESTIGATOR_2826]) or body  temperature of ≥38.0ºC 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
33
Status: Approved ,  Date: 16 March 2020(≥100.4ºF) within 24 hours prior to the planned administration of study  vaccine .
Note : Enrollment at a later date is permitted. For participants in Cohorts 2 and 3, 
clinical safety laboratory assessments should be repeated if vaccination is postponed 
and the time between clinical safety laboratory assessments and vaccination exceeds 
28days.
3. History  of malignancy  within 5 years before screening not in the following categories:
a.Participants with squamous and basal cell carcinomas of the skin and carcinoma 
in situ of the cervix may  be enrolled at the discretion of the investigator .
b.Participants with history  of malignancy  within 5 years, which is considered 
cured with minimal risk of recurrence per investigator ’s judgement, can be 
enrolled.
4. Known allergy  or history  of anaphy laxis or other serious adverse reactions to vaccines 
or vaccine components (including an y of the cons tituents of the study  vaccine).8,9
5. Has abnormal function of the immune sy stem resulting from:
a.Clinical conditions (eg, autoimmune disease or immunodeficiency )expected to 
have an impact on the immune response elicited by [CONTACT_106366].
Participants with autoimmune disease (eg, autoimmune -mediated thyroid 
disease, autoimmune inflammatory  rheumatic disease such as rheumatoid 
arthritis, and ty pe 1 or 2 diabetes mellitus) that is stable and inactive without the 
use of systemic immunomodulators and glucocorticoids may be enrolled at the 
discretion of the investigator.
b.Chronic (>10 days) or recurrent use of systemic corticosteroids within 6months 
before administration of study  vaccine.
Note : Ocular , topi[INVESTIGATOR_2855], or inhaled ster oids ar e allowed.
c.Administration of antineoplastic and immunom odulating agents (eg, cancer 
chemotherapeutic agents or systemic corticosteroids) or radiotherap ywithin 
6months before administration of study  vaccine .
6. History  of acute polyneuropathy  (eg,Guillain -Barré syndrome) or chronic idiopathic 
demy elinating polyneuropathy .
7. History  of chronic urticaria (recurrent hives), eczema, or atopic dermatitis.
8. Received hematopoietic stem cell transplant in medical history , treatment with 
immunoglobulins in the 2 months, immunoglobulins specific to RSV , human 
metapneumovirus, or parainfluenza viruses in the 12months, apheresis therapi[INVESTIGATOR_130243] 
4 months, or blood products in the 6months before the planned administration of the
study  vaccine or has an y plans to receive such treatment during the stud y.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
34
Status: Approved ,  Date: 16 March [ZIP_CODE]. Received or plans to receive:
a.Licensed live attenuated vaccines –within 28 days before or after planned 
administration of study  vaccine .
b.Other licensed (not live) vaccines –within 14 days before or after planned 
administration of study  vaccine .
10. Received an investigational drug or used an invasive investigational medical device 
within 30days or received an investigational vaccine within 6 months before the 
planned administration of study  vaccine or is currently  enrolled or plans to participate in
another investigational study  during the course of this study .
Note : Participation in an observational clinical study (ie, without intervention) is 
allowed upon approval of the sponsor.
11. Has a serious chronic disorder, including severe chronic obstruc tive pulmonary  disease 
or severe congestive heart failure, end-stage renal disease with or without dialy sis, 
clinically  unstable cardiac disease, Alzheimer’s disease, or has any condition for which, 
in the opi[INVESTIGATOR_871] , participation would n ot be in the best interest of the 
participant (eg, compromise the well -being) or that could prevent, limit, or confound the 
protocol -specified assessments.
12. Had major surgery  (as per the investigator’s judgment) within [ADDRESS_282209] fully  recovered from surgery prior to vaccination , or has 
major surgery within 6 months after administration of study  vaccine.
Note : Participants with planned surgical procedures to be conducted under local or 
locoregional anesthesia and not judged as major by [CONTACT_233843].
13. Is an employ ee of the investigator or study  site, with direct involvement in the proposed 
study  or other studies under the direction of that investigator or study  site, as well as 
family  members of the employ ees or the investigator, or an employ ee of the sponsor .
14. Has hepatitis B or C infection , including history of treated hepatitis C infection (per 
medical history ).
15. Has human immunodeficiency  virus ty pe 1 or 2 infection (per medical history ).
16. Has had major psychiatric illness and/or drug or alcohol abuse which in the 
investigator’s opi[INVESTIGATOR_130242]’s safet y and/or compliance 
with the study  procedures.
17. Cannot communicate reliably with the investigator.
18. Is unlikel y to adhere to the requirements of the study  or unlikel y to complete the full 
course of observation in the opi[INVESTIGATOR_871].
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
35
Status: Approved ,  Date: [ADDRESS_282210] ylerestrictions 
during the course of the study  to be eligible for participation:
1. Refer to Section 6.5for details regarding prohibited and restricted therapy  during the 
study .
2. Agree to follow all requirements that must be met during the study  as noted in the 
inclusion and exclusion criteria (Sections 5.1 and 5.2, respectivel y).
5.4. Screen Failures
Participant Identification, Enrollment, and Screening Logs
The investigator agrees to complete a participant identification and enrollment log to permit easy  
identification of each participant during and after the study . This document will be reviewed by 
[CONTACT_43786] -site contact [CONTACT_23853].
The participant identification and enrollment log will be treated as confidential and will be filed 
by [CONTACT_23854]. To ensure participant confidentiality , no copy  will be made. 
All reports and communications relating to the study  will identify  participants by [CONTACT_90802] . In cases where the participant is not 
randomized into the study , the date seen and age at initial informed consent will be used.
Individuals who do not meet all eligibility  criteria (screen failure) but at some point in the future 
are expected to meet the eligibility  criteria may be rescreened on one occasion only. Rescreened 
participants will be assigned a new participant number, undergo the informed consent process, 
and then restart a new screening phase .
6.STUDY VACCINE
6.1. Study Vaccine Administ ration
On Day 1, participants will receive a single IM injection of study  vaccine (ie, the Ad26/protein 
preF RSV vaccine or placebo) in the deltoid muscle . The injection will occur at the study  site
according to the overview shown in Table 2. TheAd26/protein preF RSV vaccine is composed 
of Ad26.RSV.preF (JNJ -64400141) and RSV preF protein (JNJ- 64213175) (Section 2).
Ad26.RSV.preF will be administered at a dose level ranging from 3.7×109vp to 1.6×1011vp, and 
RSV preF protein at a constant dose level of 150 µg(Table 2). Refer to Section 4.3for 
justific ation of the dose levels. Due to the different dose levels of Ad26.RSV.preF, the injection 
volumes of the study  vaccine may differ between the cohorts. Ad26.RSV.preF and RSV preF 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
36
Status: Approved ,  Date: [ADDRESS_282211] of 0.9% 
saline. The use of concomitant therap y stated in Section 6.5should be respected. Study 
vaccination pausing rules are listed in S ection 7.3.
Study  vaccine administration must be captured in the source documents and the electronic case 
report form ( eCRF ).
Ad26.RSV.preF and RSV preF protein will be manufactured and provided under the 
responsibility  of the sponsor .Ad26.RSV.preF will be supplied as a frozen liquid to be thawed 
prior to use. Labels will contain information to meet the applicable regulatory  requirements. 
Note that RSV preF protein CTM will be labelled as “RSV -F Vaccine ”. Refer to the IBs for 
Ad26.RSV.preF8andRSV preF protein9for details of the components and a list of excipi[INVESTIGATOR_840].
For a definition of study vaccine overdose, refer to Section 8.4.
6.2. Preparation/Handling/Storage/A ccountability
Preparation/Handling/Storage
Vials must be stored in a secured location under controlled temperature with no access for 
unauthorized personnel. The study  refrigerator/freezer must be equipped with a continuous 
temperature monitor and alarm andshould be equipped with back -up power sy stems. Ifthe study 
vaccine components areexposed to temperatures outside the specified temperature range, all 
relevant data will be sent to the sponsor to determine if the affected study  vaccine components 
can be used or will be replaced. The affected study  vaccine components must be quarantined and 
not used until further instruction from the sponsor is received.
An unblind ed study-site pharmacist , or other qualified individual, who will have no other study  
function following vaccination, will prepare the appropriate vials and syringes, labeled with the 
participant’s identification number, and provide the syringes for the study vaccine in a blinded 
manner to the blinded study  vaccine administrator who will perform the injection . Anunblinded 
study -site pharmacist, or other qualified individual, may also perform the vaccination but will 
have no other stud y function following vaccination .
Refer to the Investigational Product Preparation Instruction sand Study Site Investigational 
Product and Procedures Manual for additional guidance on study  vaccine preparation, handling, 
and storage.
Accountability
The investigator is responsible for ensuring that all study  vaccine received at the study  site is 
inventoried and accounted for throughout the study . The study  vaccine administered to the 
participant must be documented on the vaccine accountability  form. All study  vaccine will be 
stored and disposed of according to the sponsor’ s instructions.
Study  vaccine must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
37
Status: Approved ,  Date: [ADDRESS_282212] be available for verification by [CONTACT_103] ’s study -site monitor during on -site monitoring visits. The r eturn to the sponsor of unused 
study  vaccine will be documented on the vaccine return form. When the study  site is an 
authorized destruction unit and study  vaccine supplies are destro yed onsite, this must also be 
documented on the vaccine return form.
Potentially  hazardous materials containing hazardous liquids, such as used ampules, needles, 
syringes ,and vials ,should be disposed of immediately  in a safe manner and therefore will not be 
retained for vaccine accountability  purposes.
Study  vaccine should be dispensed under the supervision of the investigator or a qualified 
member of the study -site personnel, or by a  hospi[INVESTIGATOR_307]/clinic pharmacist. Study  vaccine will be 
supplied only to participants participating in the study . Study  vaccine may not be relabeled or 
reassigned for use by [CONTACT_48780]. The investigator agrees neither to dispense the study  
vaccine from, nor store it at, any study  site other than the study  sites agreed upon with the 
sponsor .
6.3. Measures to Minimize Bias: Randomization and Blinding
Study Vaccine Allocation
Procedures for Randomization
Central randomization will be implemented in this study . Within each cohort, p articipants will be 
randomly  assigned to the groups based on a computer -generated randomization schedule 
prepared before the study  by [CONTACT_43754] . In Cohort 1, the 
randomization ratio is 2:2:2:2:1 to Groups 1 to 5, respectivel y, in Cohort 2, the randomization 
ratio is 2:2:1 to Groups 6to 8, respectively, and in Cohort 3, the randomization ratio is 1:2:[ADDRESS_282213] these participants at the discretion of the 
sponsor. Any replacement participant will be assigned to the same group as the original 
(discontinued) participant. The replacement participant’s randomization number will equal the 
randomization number of the discontinued participant [PHONE_3548] (eg, participant 0001 would be 
replaced by [CONTACT_3445] 1001). These additional participants should also be randomized through 
IWRS. No replacements or additional randomizations will be done for withdrawals after 
vaccination.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
38
Status: Approved ,  Date: 16 March 2020Blinding
The investigator will not be provided with randomization codes until database lock of the final 
analysis of the complete study . The codes will be maintained within the IWRS, which has the 
functionality  to allow the investigator to break the blind for an individual participant.
At the sponsor level, unblinding (at the participant level) will occur at the time of the primary  
analysis for each cohort (Section 9.5). From the primary  analysis onwards, group level results 
may be shared as needed, however, efforts will be made to preserve the blinding to the individual 
participant allocation.
Data that may potentially  unblind the study  vaccine assignment ( eg,immunog enicitydata,study  
vaccine preparation/accountability  data, study  vaccine allocation) will be handled with special 
care to ensure that the integrity  of the blind is mainta ined and the potential for bias is minimized. 
This can include making special provisions, such as segregating the data in question from view 
by [CONTACT_473], clinical team, or others as appropriate until the time of database lock and 
unblinding.
The investigator may in an emergency  determine the identity  of the study  vaccine by [CONTACT_233844]. While the responsibility  to break the study  vaccine allocation code in emergency 
situations resides solely  with the investigator, it is recommended that theinvestigator contact s
the sponsor if possible to discuss the particular situation, before breaking the blind. Telephone 
contact [CONTACT_233845] 24hours per day, 7days per week. Inthe event the 
blind is broken, the sponsor must be inf ormed as soon as possible. The date, time, and reason for 
the unblinding must be documented by [CONTACT_8784],in the appropriate section of the eCRF , and in 
the source document. The documentation received from the IWRS indicating the code break 
must be retained with the participant ’s source documents in a secure manner. Theinvestigator is 
advised not to reveal the study  vaccine assignment to the study -site personnel or sponsor 
personnel/sponsor representative.
The pharmacist or qualified individual with primary responsibility  for study  vaccine preparation 
and dispensing will be unblinded to study  vaccine allocation (Section 6.2).
Participants who have had their study  vaccine assignment unblinded should continue to return 
for scheduled evaluations .
6.4. Study Vaccine Compliance
Study  vaccine will be IM administered b y a blinded study  vaccine administrator (ie, a trained and 
qualified study  nurse, medical doctor, or otherwise qualified healthcare professional) at the study 
site. The unblinded study -site pharmacist, or other qualified individual, may also perform the 
vaccination, but will have no other study  function following vaccination. Details of each 
administration will be recorded in the eCRF (including date and time of injection). For blinding 
procedures, see Section 6.3.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
39
Status: Approved ,  Date: [ADDRESS_282214] be recorded in the eCRF 
at screening (all cohorts) and additionally  on Day  1 for Cohorts 2 and 3.
Concomitant therapi[INVESTIGATOR_160134]/antipy retic medications and nonsteroidal 
anti-inflammatory  drugs, corticosteroids, and antihistaminic must be recorded in the eCRF until 
28 day s after vaccination. All other concomitant therapi[INVESTIGATOR_233805] e CRF if 
administered in conjunction with new or worsening AEs reported per protocol requirements 
outlined in Section 10.3, Appendix 3.
Analgesic/antip yretic medications and nonsteroidal anti-inflammatory  drugs may be used after 
vaccination onl y in cases of medical need (eg, fever or pain). Use of these medications as routine 
prophy laxis before vaccination is discouraged.
Information on concomitant use o f herbal supplements or vitamins will not be collected.
Useof systemic corticosteroids must be documented during the study . Use of ocular, topi[INVESTIGATOR_2855], or 
inhaled steroids during the study  isallowed, whereas chronic (>10 days) or recurrent use of 
systemic corticosteroids during the study  is prohibited . Antineoplastic and immunomodulating 
agents or radiotherap y are prohibited during the study . Ifchronic use of systemic corticosteroids 
or antineoplastic or immunomodulating agents becomes medicall y indicated during the study  for 
any participant, the sponsor should be notified.
Vaccination with licensed live attenuated vaccines within 28 days of study  vaccination 
(ie,before orafter) is prohibited. Other licensed (not live) vaccines (eg, influenza, tetanus, 
hepa titis A, hepatitis B, rabies) should be given at least 14days before (or at least 14 days after) 
administration of study  vaccine in order to avoid potential confusion of adverse reactions and 
potential immune interference. If a vaccine is indicated in a postexposure setting (eg,rabies or 
tetanus), it must take priority  over the study  vaccine.
Use of any experimental medication (including experimental vaccines other than the study  
vaccine) during the stud y is not allowed.
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
6.6. Intervention After the End of the Study
Participants will be instructed that study  vaccine will not be made available to them after they 
have comple ted/discontinued study  vaccination.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
40
Status: Approved ,  Date: 16 March [ZIP_CODE].DISCONTINUA TION OF STUDY VACCIN ATION AND P ARTICIPA NT 
DISCONTINUA TION/ WITHDRA WAL
7.1. Discontinuation of Study Vaccin ation
A participant ’s study  vaccination must bediscontinue d if:
The participant withdraws consent to receive study  vaccination .
The investigator believes that for safet y reasons or reactogenicit yreasons (eg,AE) it is in 
the best interest of the participant to discontinue study  vaccination.
Study  vaccine assigned to the participant who discontinued study  vaccin ation may not be 
assigned to another participant. Additional participants will be entered to ensure the 
protocol -specified number of participants complete the study .
7.2. Contraindications to Study Vaccin ation
The following events assessed by [CONTACT_233846] a temporary  contraindication to 
study  vaccination:
Acute illness at the planned time of vaccination. This does not include minor illnesses, such 
as diarrhea or mild upper respi[INVESTIGATOR_2826].
Fever (bod y temperature of ≥38.0°C [ ≥100.4ºF] ) at the planned time of vaccination.
If any  of these events occur at the planned time of vaccination, the participant may be vaccinated 
up to, and no later than, 10 day s after the planned vaccination , or be withdrawn from vaccination 
at the discretion of the investigator .
Note : For participants in Cohorts 2 and 3, clinical safety laboratory assessments should be 
repeated if vaccination is postponed and the time between clinical safety laboratory assessments
and vaccination exceeds 28 days.
7.3. Study Vaccination Pausing Rules
The PI(s) and sponsor team members (ie, SRP/SRS) will monitor the study  vaccination pausing 
rules listed below . If vaccination is considered to raise significant safety  concerns (ie, if at least 
one of the study  vaccination pausing rules has been met), further vaccination of participants will 
be paused until the DRC review of all available data is carried out and subsequent 
communication between the sponsor and the PI(s) takes place. The DRC will review blinded data 
first but is entitled to and has the right to require submission of unblinded data if deemed 
necessary . When afirst DRC meeting has been triggered by [CONTACT_172719] a given study 
vaccination pausing rule, the DRC will convene thereafter for each additional participant 
meeting that pausing rule. Possible actions upon review include, but are not limited to,study 
suspension, study  adaptation, or discontinuation of further vaccination.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
41
Status: Approved ,  Date: [ADDRESS_282215] of study  vaccina tion pausing rules applies for concerned AEs that occur up to 
28days after vaccination and concerned SAEs:
1.One or more participants experience an SAE or other potentiall y life-threatening (Grade 4) 
event that is determined to be related to stud y vaccine; OR
2.One or more participants experience anaphy laxis clearl y not attributable to other causes than 
vaccination with study  vaccine; OR
3.Two or more participants experience a Grade 3 or 4 unsolicited AE of the same type, 
determined to be related to study  vaccin e, that persists for 72 hours or longer; OR
4.Two or more participants experience a Grade 3 or 4 solicited systemic AE of the same type, 
determined to be related to study  vaccine, that persists for 72 hours or longer; OR
5.Two or more participants experience apersistent (upon repeated testing) Grade 3 or 4 
laboratory  abnormalit y related to the same laboratory  parameter and considered related to 
study  vaccine, that persists for 72 hours or longer; OR
6.Death of any participant considered related to study  vaccine or if the causal relationship to 
study  vaccine cannot be excluded.
Note : All cases of death will be sent to the DRC. Upon their review, the DRC will decide 
whether a study pause is required.
For study  vaccination pausing rule 5: to assess abnormal laboratory  values, the test must be 
repeated at least once, within 48 hours of the study  site becoming aware of the abnormal value.
After each DRC review of similar AEs, the DRC will indicate the conditions under which it 
requires further notification and review of the subsequent similar AEs.
To enable prompt response to a situation that could trigger study  vaccination pausing rules 3, 4,
or 5, the investigator should update the eCRF with information on any Grade 3 or 4 AE on the 
same day  that the AE is reported .
Also, the investigator should notify  the sponsor’s medical monitor (AND transmit the SAE form 
electronically  to Global Medical Safet y Operations, if applicable), immediately  and no later than 
24 hours after becoming aware of any related AEof Grade 3 or above AND update the eCRF 
with relevant information on the same day the AEinformation is collected. Athorough analysis 
of all Grade 3 (or above) cases will be carried out by  [CONTACT_456]’s medical monitor, irrespective 
of whether the criteria for pausing the study  are met. Based on the pausing criteria, the sponsor’s 
medical monitor will then decide whether a study  pause is warranted. Allstudy  sites will be 
notifie d immediately  in case of a study  pause. The sponsor’s medical monitor is responsible for 
the immediate notification of the DRC members and coordination of a DRC meeting in case of a 
study  pause.
Vaccinations for the study  may be suspended for safet y concer ns other than those described 
above, or before study  vaccination pausing rules are met, if, in the judgment of the DRC, 
participant safety  may  be threatened.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
42
Status: Approved ,  Date: 16 March 2020Resumption of vaccinations will start only upon receipt by [CONTACT_233847] . The study  site(s) will be allowed to resume activities upon receipt 
of a written notification from the sponsor. The communications from the DRC will be forwarded 
by [CONTACT_233848] ( IEC)/Institutional Review Board (IRB)
and by  [CONTACT_233849], according to local standards and regulations .
In addition to the study  vaccination pausing rules, the sponsor’s medical monitor or the PI(s) 
(upon consultation with the sponsor’s med ical monitor) may  initiate a DRC review for any  single 
event or combination of events which, in their professional opi[INVESTIGATOR_1649], could jeopardize the safet y 
of the participants or the reliability  of the data.
7.4. Participant Discontinuation/ Withdrawal From the Study
Each participant has the right to withdraw from the study  at any time for any reason without 
affecting the right to treatment by [CONTACT_093]. The investigator should make an attempt to 
contact [CONTACT_233850] -up. Although the 
participant is not obliged to give reason(s) for withdrawing prematurel y, the investigator should 
make a reasonable effort to ascertain the reason(s) while fully  respecting the participant’s rights.
A participant will be withdrawn f rom the study  for any  of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
Repeated failure to comply  with protocol requirements orto cooperate with the study -site 
personnel
Decision b y the sponsor or the investigator to stop or cancel the study
Decision b y local regulatory authorities or IEC /IRBto stop or cancel the study
Any unnecessary  study discontinuation should be avoided. When a participant withdraws before 
study completion , the reason for withdrawal is to be documented in the eCRF and in the source 
document. All efforts should be made to complete and report the observations as thoroughl y as 
possible. Study  vaccine assigned to the withdrawn participant may not be assigned to another 
participant. Participants who withdraw will be replaced, as long as the participant has not been 
vaccinated (Section 6.3).
An early exit visit will be conducted for those participants who are unable to continue 
participation in the study and withdraw from the study  before Day  183, but who do not withdraw 
consent (Section 1.3). Participants who wish to withdraw consent from participation in the study 
will be offered an early exit visit (prior to formal withdrawal of consent). They  have the right to 
refuse.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
43
Status: Approved ,  Date: [ADDRESS_282216] the participant and determine the reason (s)for discontinuation/withdrawal. 
Themeasures taken to follow up must be documented.
7.4.1. Withdrawal From the Use of Research Samples
Withdrawal From the Use of Samples in Future Research
The participant may withdraw consent for use of samples for research (refer to Long -term 
Retention of Samples for Additional Future Research in Section 10.4, Appendix 4). In such a 
case, samples will be destroy ed after they are no longer needed for the clinical study . Details of 
the sample retention for research are presented in the main I CF.
7.5. Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly  fails to return for 
scheduled visits and is unable to be contact[CONTACT_56821]. A participant cannot be deemed 
lost to follow -up until all reasonable efforts made by [CONTACT_1758] -site personnel to contact [CONTACT_233851]. The following actions must be taken if a participant fails to return 
to the study  site for a required study  visit:
The study -site personnel must attempt to contact [CONTACT_233852], to counsel the participant on the importance of maintaining the 
assigned visit schedule, to ascertain whether the participant wishes to or should continue in 
the study .
Before a participant is deemed lostto follow -up, the study -site personnel must make every 
reasonable effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls, 
e-mails, fax, and, if necessar y, a certified letter to the participant’s last known mailing 
address, or local equivalent methods), and to determine the reason for 
discontinuation/withdrawal. These contact [CONTACT_21457]’s study  file.
Should the participant continue to be unreachable, he or shewill be considered to have 
withdra wn from the study .
Should a study  site close, eg, for operational, financial, or other reasons, and the investigator 
cannot reach the participant sto inform them, their contact [CONTACT_233853] y site.
8.STUDY ASSESSMENTS A ND PR OCEDURES
Overview
The Schedule of Activities (Section 1.3)summarizes the frequency  and timing of 
immunogenicit yand safety  measurements applicable tothis study . Unscheduled visits may be 
performed based on the investigator’s clinical judgment and may include further evaluations, as 
needed .
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
44
Status: Approved ,  Date: [ADDRESS_282217] body temperature and solicited injection site and 
systemic signs and s ymptoms will be provided to the participants on the day  of study  vaccination 
(Day  1). The participant diary  includes instructions on how to capture the data and grading scales 
to assess severity  of the signs and symptoms. The study -site personnel will be responsible for 
providing appropriate training to the participant to avoid missing or incorrect data. 
Theparticipant diary  will be reviewed by [CONTACT_1758] -site personnel at the Day 8  v isit. If the 
participant diary  review is missed, the participant diary  will be reviewed during the following 
visit. Thermometers will be given to all participants on the day of study  vaccination (Day 1)and 
should be returned to the study  site at the end of the study /early  withdrawal . Participants will 
also be provided with a ruler on the day of study  vaccination (Day  1) to measure local injection 
site reactions.
If multiple assessments are scheduled for the same timepoint, it is recommended that procedures 
be performed in the following sequence: vital signs , nasal sampling , blood draws . If needed,
assessments may be performed onanother day within the applicable visit window. Actual dates 
and times of assessments will be recorded in the source document and in the eCRF.
The total blood volume to be collected from each participant will be approximately  240 mL 
(Cohort 1) or 260mL (Cohorts 2 and 3).
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues with the 
samples .
Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form.
Refer to the Schedule of Activities (Section 1.3)for the timing and frequency  of all sample 
collections.
Instructions for the collection, handling, storage, and shipment of samples are found inthe 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the labor atory  manual.
Study -specific Materials
The investigator will be provided with the following supplies:
IBfor A d26.RSV.preF8
IB for RSV preF protein9
Study Site Investigational Product and P rocedures M anual
Laboratory  manual
Investigational Product Preparation Instructions
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
45
Status: Approved ,  Date: 16 March 2020Participant d iaryand instructions for use
Rulers (to measure diameter of an y erythema and induration/swelling)
Thermometers
Laboratory  kits
Contact I nformation page(s)
Study  protocol
IWRS Manual 
Electronic data capture (eDC)Manual /eCRF completion guidelines
Any other manual, as applicable
Wallet card
Sample I CF
8.1. Immunogenicity Assessments
Venous blood samples of approximately  10 and 50 mL will be collected for the determinati on of 
humoral and cellular immune responses, respectively (Table 3), at the timepoints indicated in the 
Schedule of Activities (Section 1.3).Nasosorption samples using SAM strips will be collected at 
the timepoints indicated in the Schedule of Activities (Section 1.3), and will be used for 
immunogenicit y assessments including, but not limited to,determination of antigen -specific 
immunoglobulin (IgG and IgA ) (Table 3).
Sample collection and processing will be performed by [CONTACT_1758] -site personnel according to 
current versions of approved standard operating procedures.
Table 3: Summary of Possible Immunogenicity Assays (Hum oral and Cellular)
Assay Purpose
Primary and secondary endpoints
Pre-F protein binding antibody (ELISA) Analysis of antibodies binding to RSV F protein in prefusion form
RSV A2 neutralization Analysis of neutralizing antibodies to the A2 strain
IFN- γ (ELISpot) T-cell IFN -γ responses to RSV F protein peptides
Exploratory endpoints
Post-F protein binding antibody (ELISA) Analysis of antibodies binding to RSV F protein in postfusion form
Antigen -specific T -cell immune responses Analysis of T -cell responses to RSV F protein peptide -stimulated 
PBMCs (including, but not limited to, CD4+/CD8+, IL-2, IFN -γ, 
TNF -α, activation markers and memory) using ICS or CyTOF
RSV strain cr oss-neutralization Analysis of cross -neutralizing antibodies to B and/or other 
Astrain(s)
Antibody specificity and functional 
characterizationAnalysis of pre-and post -F antibody specificity by [CONTACT_233823], competition ELISA ,and epi [INVESTIGATOR_9230] m appi[INVESTIGATOR_007]. 
Functional characterization of antibodies including, but not limited 
to, ADCC, ADCP, avidity, immunoglobulin isotype ,and functional 
VNAs to other respi[INVESTIGATOR_233806]18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
46
Status: Approved ,  Date: 16 March 2020Analysis of nasal antibodies to RSV 
including, but not limited to, IgA and IgGAnalysis of nasal antibodies binding to RSV F protein in prefusion 
and/or postfusion form in nasal samples
Adenovirus neutralization assay Analysis of neutralizing antibodies to Ad26
ADCC = antibody -dependent cell-mediated cytotoxicity; ADCP = antib ody-dependent cellular phagocytosis; 
CyTOF =cytometry by [CONTACT_233824]; IL = interleukin; PBMC =peripheral bone marrow cell; TNF = tumor necrosis factor.
Immunogenicit y samples will be prioritized as outlined in the laboratory  manual.
8.2. Safety  Assessments
Safety  will be evaluated throughout the study  from signing of the ICF until the last study -related 
activity ,or until the participant has been deemed lost to follow -up after demonstration of due 
diligence of follow -up efforts.
Key safety assessments will include the monitoring of AEs, physical examinations, vital signs, 
and clinical safety  laboratory  assessments .
AEs will be reported and followed by [CONTACT_23803] 8.3 and 
Section 10.3, Appendix 3.
Any clinicall y significant abnormalities (including those persisting at the end of the study /early 
withdrawal )will be followed by [CONTACT_233854] (retu rn to baseline) or 
until a clinically  stable condition is reached , oruntil the participant has been deemed lost to 
follow -up after demonstration of due diligence of follow -up efforts .
Details regarding the DRC are provided in Section 9.6.
The study  will include the following evaluations of safet y and reactogenicity  according to the 
timepoints provided in the Schedule of Activities (Section 1.3).
8.2.1. Physical Examination s
A physical examination (including height and body  weight) will be carried out at screening 
(Cohorts 2 and 3) or on Day 1 (prevaccination) (Cohort 1). At all other visits, an abbreviated, 
symptom -directed physical examination will be performed if deemed neces sary by [CONTACT_233855], clinically  relevant symptoms, and medical 
history . A symptom -directed physical examination may be repeated if deemed necessary  by [CONTACT_1275].
Physical examinations will be performed by  [CONTACT_233856] a designated medically -trained 
clinician . Any clinically  relevant abnormalities or changes in severity  observed during the review 
of body  systems should be documented in the eC RF.
8.2.2. Vital Signs
Body temperature (oral route preferred), heart rate(beats per minute) , respi[INVESTIGATOR_2842](breaths 
per minute) , and s ystolic and diastolic blood pressure (mmHg) will be assessed.
Blood pressure and heart rate measurements will be assessed , if possible, with a completely  
automated device. Manual techn iques will be used only  if an automated device is not available.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
47
Status: Approved ,  Date: 16 March 2020Systolic and diastolic blood pressure (supi[INVESTIGATOR_050]) and heart and respi[INVESTIGATOR_233807] [ADDRESS_282218] in a quiet setting without distractions 
(eg,television, cell phones). Vital signs measurements should be taken before nasal sampling 
and blood draws , if applicable.
Confirmatory  vital signs measurements can be performed if inconsistent with a prior 
measurement. Any clinically  relevant abnormalities or changes in severit y should be documented 
in the eCRF .
8.2.3. Clinical Safety Laboratory  Assessments
InCohorts 2 and3, blood samples for biochemistry  and hematology  will be collected as noted in
Table 4at the timepoints indicated in the Schedule of Activities (Section 1.3).All clinical safet y 
laboratory  anal yses will be performed at the central laboratory .
Table 4: Protocol -required Clinical Laboratory Assessments
Biochem istry Panel Hem atology Panel
sodium hemoglobin
potassium white blood cell count with differential
creatinine platelet count
blood urea nitrogen prothrombin timea
aspartate aminotransferase activated partial thromboplastin timea
alanine aminotran sferase
a.Will be measured at screening only .
Review and Grading of Laboratory Data
The investigator must review the laboratory  results, document this review, and record any 
clinically  relevant changes occurring during the study  in the AE section of the eCRF. 
Thelaboratory  reports must be filed with the source documents.
Laboratory  values will be initially  evaluated by [CONTACT_233857]. Abnormal values outside the central laboratory normal range will be graded according to 
the FDA Guidance document “Toxicity  Grading Scale from Healthy  Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials ”(Section 10.2, Appendix 2). 
Laboratory  values within central laboratory normal limits will not be FDA graded and will be 
considered as normal.
Reporting Laboratory Abnormalities as AEs
Any clinicall y significant abnormal laborat ory value within 28 days after vaccination that falls 
outside the central laboratory normal range will be captured as an AE. Laboratory  values outside 
normal ranges that are not clinically  significant in the judgment of the investigator should not be 
recor ded as AE s. Any  laboratory  value falling within the central laboratory normal range will not 
be severit y graded or recorded as an AE, regardless of whether the value falls within FDA range s
for Grade 1 or higher.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
48
Status: Approved ,  Date: [ADDRESS_282219] be repeated at the next scheduled visit or sooner based on the investigator’s 
judgment, however Grade 3 or higher abnormalities should be retested within 48 hours.
Screening Procedures (Cohorts 2 and 3 Only)
For entry  into the study , each participant must be healthy  on the basis of clinical laboratory  tests 
performed at screening. Refer to inclusion criterion [ADDRESS_282220] operating procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_43765].
For further details on AEs and SAEs (Definitions and Classifications; Attribution Definitions; 
Severity  Criteria; Special Reporting Situations; Procedures) as well as product qualit y 
complaints (PQCs) , refer to Section 10.3, Appendix 3.
8.3.1. Time Period and Frequency  for Collecting AEand SAEInformation
AEs and special reporting situations, whether serious or nonserious, that are related to study 
procedures or that are related to noninvestigational sponsor products will be reported from the 
time a signed and dated ICF is obtained until the end of the study/earl y withdrawal .
Clinically  relevant medical events not meeting the above criteria and occurring between signing 
of ICF and date of vaccination will be collected on the Medical History  eCRF page as 
pre-existing conditions.
Any solicited local (injection site) or systemic AEs occurring during the 30-minute 
postvaccination observation period (or longer if deemed necessary  by [CONTACT_093]) will be 
documented by [CONTACT_1758] -site personnel following this observation period. Solicited AEs 
collected through a participant diary  will be recorded from the time of vaccination until 7days 
after vaccination.
All other unsolicited AEs and special reporting situations, whether serious or nonserious, will be 
reported from the time of vaccination until 28 days after vaccination. All AEs and SAEs leading 
to discontinuation of the study  vaccination (regardless of the causal relationship ) are to be 
reported from the moment of vaccination until completion of the participant’s last study -related 
procedure, which may include contact [CONTACT_233858] -up. All other SAEs (regardless of the 
causal relationship ) are to be reported from the time of vaccination until the end of the 
study /early  withdrawal.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
49
Status: Approved ,  Date: [ADDRESS_282221] be completed and reviewed by a physician from the study  site, and 
transmitted to the sponsor within 24 hours. The ini tial and follow- up reports of an SAE should be 
transmitted electronically or by  [CONTACT_6972] (fax).
The sponsor will evaluate any safet y information that is spontaneously  reported by [CONTACT_117197].
8.3.2. Method of D etecting AEsand SAEs
Care will be taken not to introduce bias when detecting AEs or SAEs . Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE
occurrence.
Solicited AEs
Solicited AEs are used to assess the reactogenicity  of the study  vaccine and are predefined local 
(at the injection site) and sy stemic events for which the participant is specifically  questioned and 
which are noted b y participants in their participant diary .
After vaccination with study  vaccine on Day 1, participants will remain under observation at the 
study  site for a minimum of [ADDRESS_282222] solicited 
signs and symptoms in theparticipant diary  for 7 days after vaccination. All participants will be 
provided with theparticipant diary  and instructions on how to complete the diary  (Section 8). 
The study -site personnel will transcribe the information provided by [CONTACT_233859]. After review and verbal discussion of the initial participant diary  
entries with the participant, the investigator will complete his or her own assessment in the 
relevant sections of the eCRF. Once a solicited sign or symptom from the participant diary  is 
considered to be of severity  Grade 1 or above during the investigator’s assessment , it will be 
recorded as a solicited AE.
Solicited Injection Site AEs
Participants will be asked to note in the participant diary  occurrences of injection site 
pain/tenderness at the study  vaccine injection site daily  for 7 days after vaccination (day of 
vaccination and the subsequent 7 days). The extent (largest diameter) of any erythema and 
swelling at the injection site should be measured (using the ruler supplied) and recorded daily. 
The case definitions for solicite d injection site events can be found in Gidudu et al.7and Kohl et 
al.[ADDRESS_282223] the body  temperature (oral route preferred) in 
the participant diary  in the evening of the day of vaccination, and then daily  for the next 7days 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
50
Status: Approved ,  Date: [ADDRESS_282224] body  temperature of that day  will be used in the eCRF.
Fever is defined as endogenous elevation of body  temperature ≥38.0°C [≥100.4ºF] , as recorded 
in at least one measurement.14
Participants will also be instructed on how to note signs and sy mptoms in the participant diary  on 
a daily basis for 7 days aftervaccination (day of vaccination and the subsequent 7 days), for the 
following events: fatigue, headache, nausea, and myalgia.
Unsolicited AEs
Unsolicited AEs are all AEs for which the participant is not specifically  questioned in the 
participant diary.
8.3.3. Follow -up of AEsand SAEs
AEs, including pregnancies in partners of male participants, will be followed by [CONTACT_117188] 10.3 , Appendix 3.
8.3.4. Regulatory  Reporting Requirements for SAEs
The sponsor assumes responsibility  for appropriate reporting of AEs to the regulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs). The investigator 
(or sponsor where required) must report S[LOCATION_003]Rs to the appropriate IEC/IRB that approved the 
protocol unless otherwise required and documented by [CONTACT_6179]/IRB . A S[LOCATION_003]R will be reported 
to regulatory  authorities unblinded. Participating investigators and IEC/IRB will receive a 
blinded S[LOCATION_003]R summary , unless otherw ise specified.
8.3.5. Pregnancy
All initial reports of pregnancy  in female participants or partners of male participants must be 
reported to the sponsor by [CONTACT_1758] -site personnel within 24 hours of their knowledge of the 
event using the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes 
(eg,spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy ) are 
considered SAEs and must be reported using the SAE Form.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required.
8.4. Treatment of Overdose
For this study , any dose ofthe Ad26/protein preF RSV vaccine greater than the 
protocol -specified dose will be considered an overdose. Thesponsor does not recomme nd 
specific intervention for an overdose.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
51
Status: Approved ,  Date: 16 March 2020In the event of an overdose, the investigator or treating ph ysician should:
Contact [CONTACT_44686] m onitor immediately .
Closely  monitor the participant for AE/SAE and laboratory  abnormalities until resolution .
Document the quantit y of the excess dose in the eCRF.
Report as a special reporting situation .
8.5. Genetics
Genetics are not evaluated in this study .
8.6. Medical Resource Utilization and Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are not 
evaluated in this study .
9.STATISTICA L CONSIDERA TIONS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical methods to be used to analy ze the immunogenicity  and safet y data is 
outlined below. Specific details will be provided in the s tatistical analysis plan(SAP) .
9.1. Statistical Hy potheses
No formal statistical testing of safet y orimmunogenicity data is planned; data will be analy zed 
descriptivel y.
9.2. Sample Size Determination
9.2.1. Immunogenicity  (Cohort 1)
The primary  objective of Cohort 1 is to explore the dose-response relationship of humoral 
immune responses (as measured by [CONTACT_233826] )induced by [CONTACT_233860]26/protein preF RSV vaccine .
Assum ing:
10% of exclusions (eg, drop -outs, missing samples, and major protocol deviations impacting 
immunogenicit y data)
a standard deviation on the log 2scale of the preF ELISA of 1.3 on Day 15 and 1.1 on 
Day 183 for all dose levels
4 dose levels
The l inear model log 2(preF ELISA timepoint ) = GMT preF ELISA Ad26/protein preF RSV vaccine (1x1011vp/150 µg),timepoint + 
slope × #titration stepsprovides a standard error for the slope of 0.052 on Day 15 and 0.040 on 
Day 183 with 50 participants per arm. This is deemed sufficient for this exploratory  study .
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
52
Status: Approved ,  Date: 16 March [ZIP_CODE].2.2. Safety  (Cohorts 1, 2, and 3)
Placebo recipi[INVESTIGATOR_233808] y assay s.
Theobservation of 0 events (eg ,SAEs) is associated with 95% confidence that the true event rate
is below the rates specified in the below table for the considered number of participants .
Table 5: Upper Limit of the 95% One-sided Confidence Interval if no Cases are Observed for Different 
Sample Sizes
Sample Size N=25 N=50 N=75
UL 95% one-sided CI 11.3% 5.8% 3.9%
CI = confidence interval; N = number of participants; UL = upper limit.
The table below provides the probability  of observing at least one AE in a group of the 
considered sample size given several true AErates .
Table 6: P robability of Observing at Least One AEin a Group of the Considered Sample Size Given 
Several True AE Rates
True AE Rate (%)Probability of Observing at Least One AEin N Participants (%)
N=25 N=50 N=75
0.5 12 22 31
1 22 39 53
2.5 47 72 85
10 93 99 100
25 100 100 100
50 100 100 100
N = number of participants.
9.3. Populations for A nalyses
Vaccine assignment will follow the as -treated principle.
The Full Analysis Set (FAS) will include all participants who were randomized and received the 
study vaccine, regardless of the occurrence of protocol deviations. All safety  and participant 
information anal yses will be based on the FA S.
The Per -protocol Immunogenicity (PPI) Set will include all participants who were randomized 
and received thestudy vaccine , and for whom immunogenicit y data areavailable, excluding 
participants with major protocol deviations expecting to impact the immunogenicity  outcomes.
The analysis of all immunogenicit y endpoints will be based on the PPI [CONTACT_55866]. For key tables, 
sensitivity  immunogenicity  analy ses might also be performed on the FAS.
9.4. Statistical A nalyses
The SAP will be finalized prior to database lock of the primary  analysisand will include a more 
technical and detailed description of the statistical anal yses described in this section. This section 
is a summary  of the planned statistical analyses of the most important endpoints including 
primary  and key secondary  endpoints.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
53
Status: Approved ,  Date: 16 March [ZIP_CODE].4.1. Participant Information
For all participants, demographic characteristics (eg, age, height, body  weight, BMI , race, and 
gender) and other baseline characteristics will be tabulated and summarized descriptively by 
[CONTACT_9084] .
9.4.2. Immunogenicity  Analys es
No formal statistical testing of immunogenicit y data is planned. Immunogenicity  data will be 
analyzed descriptively  by [CONTACT_233861] . In addition, for a selection of tables, data maybe 
pooled over cohorts.
Descriptive statistics ( eg, geometric mean and 95% confidence interval [ CI]for ELISA and VNA
data; median and quartiles for ELISpot) will be calculated for continuo us immunologic 
parameters at all timepoints. For the humoral assay s, geometric mean fold rises from baseline 
and corresponding 95% CIsmight additionally  be calculated. Baseline is considered as the last 
available assessment before vaccination. Graphical representations of immunologic parameters 
will be made as applicable.
Frequency  tabulations will be calculated for discrete (qualitative) immunologic parameters as 
applicable.
To explore the dose-response relationship between preF ELISA and different dose levels of the
Ad26/protein preF RSV vaccine, a linear regression model will befitted for each timepoint 
separately , using data of the active groups of Cohort 1, with the log-transformed preF ELISA 
titers at the considered timepoint as dependent variable, the number of titration steps as 
independent variable, and the geometric mean titer (GMT) of preF ELISA of the Ad26/protein 
preF RSV vaccine (1×1011vp/150 µg) at the considered timepoint as a fixed intercept.
The linear model log 2(preF ELISA timepoint ) = GMT preF ELISA Ad26/protein preF RSV vaccine (1x1011vp/150 ug),timepoint + 
slope ×#titration steps will initially  be fitted for the active groups of Cohort 1 but may be 
extended in a later stage with data of the active groups of Cohorts 2 and 3. A similar model may 
be fitted as well for other assay s.
Depending on the model fit, other models (eg,log-linear models or EMAX models) may be 
explored as well.
The incidence of neutralizing antibodies to Ad26 might be summarized for participants who are 
positive for antibodies to Ad26.
Other immunogenicit y analy ses may be performed to further characterize the immune responses 
that are generated.
The primary  analysis set for the immunogenicit y analy sisis the PPI [CONTACT_55866]. As a sensitivity  analysis, 
key tables may  also be based on the FAS.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
54
Status: Approved ,  Date: 16 March [ZIP_CODE].4.3. Safety  Analyses
No formal statistical testing of safet y data is planned. Safety  data will be analyzed descriptively  
by [CONTACT_233828] . In addition, for a selection of tables, data of Cohorts 2 and 3 may be 
pooled. All safet y analyses will be based on the FAS.
AEs (Solicited and Unsolicited)
Solicited local (injection site) and sy stemic AEs will be summarized descriptively .Solicited AEs 
shown in the tables and listings will be based on the overall assessment of the investigator. 
Theoverall frequencies per group as well as frequencies according to severity  and duration will 
be calculated for solicited AEs. In addition, the number and percentages of participants with at 
least one solicited local (at the injection site) or s ystemic AE w ill be presented.
The verbatim terms used in the eCRF by [CONTACT_233862] (MedDRA). All reported AEs with onset during the 
active vaccination phase (ie, AEs occurring from the time of vaccination until 28 days after 
vaccination) and all SAEs will be included in the analysis. For each AE, the number and 
percentage of participants who experience at least oneoccurrence of the given event will be 
summarized by [CONTACT_19313]. Frequency tables of unsolicited AEs, separately for all and study 
vaccine -related, will be presented b y system organ class and preferred t erm.
Summaries, listings, datasets, or participant narratives may  be provided, as appropriate, for those 
participants who die, who discontinue study  vaccination due to an AE, or who experience a 
severe AE or an SAE.
Summaries and/or listings may be provided separatel y for AEs with onset outside the above 
defined timeframe (ie, bey ond 28 day s after vaccination) .
Clinical Laboratory T ests(Cohorts 2 and 3 only)
Laboratory  abnormalities will be determined according to the FDA toxicity  grading tables 
(Section 10.2, Appendix 2 ) or, for tests for which no grades are available, in accordance with the 
normal ranges of the clinical laboratory . Anylaboratory  value shown as a "graded "value in the 
FDA table that is within central laboratory  normal ranges will not be graded for severity .
Vital Signs
A tabulation of the distribution of body  temperatures per half degree intervals will be provided. 
For systolic and diastolic blood pressure and heart and respi[INVESTIGATOR_2842], the percentage of 
participants with values bey ond clinicall y relevant li mits will be summarized .
Physical Examination
A listing for ph ysical examination abnormalities will be generated .
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
55
Status: Approved ,  Date: 16 March [ZIP_CODE].5. Planned Analyses
The following anal yses will be performed:
Cohort 1 primary  analysis will include 14-day immunogenicit y and28-day safety  dataof all 
groups in Cohort 1. Thesponsor will be unblinded for Cohort 1 at the time of the primary  
analysis of Cohort 1, and the blind will be maintained at the participant and study  site level 
up to study  end.
Cohorts 2 and 3 primary analysis will include 28-day safety data of all groups in Cohorts 2 
and 3. If 14-day immunogenicity  data are available at the time of the primary  analysis, these 
will be included as well, otherwise these will be analyzed at a later timepoint. Thesponsor 
will be unblinded for Cohorts 2 and 3 at the time of the primary  analysis, and the blind will 
be maintained at the participant and study  site level up to study  end.
Final analysisat the end of the study  will include safety  and immunogenicity  data from all 
cohorts .Data collecte d up to the time of the last visit for the last participant will be included 
in the anal ysis. This analy sis will be performed on unblinded data.
Note : The final analysis might be done per cohort, depending on the timing .
9.6. Data Monitoring Committee or Other Review Board
An internal DRC will be established for this study  (Section 4.1). The DRC will convene, 
according to their charter, to discuss any safet y issues and any situation meeting a specific study 
vaccination pausing rule (Section 7.3). The DRC will consist of sponsor personnel not directly 
involved in the conduct of the study  and who have expertise in clinical study  conduct and 
vaccines, at least one medical expert [INVESTIGATOR_233877], at least one statistician; and 
a safety  expert. Committee membership responsibilities, authorities, and procedures will be 
documented in its charter. The PI(s) and SRP/ SRSwill inform the DRC of any  AE of concern.
In addition, the DRC will review :
All Cohort 2 safet y data collected up to the time the 20thparticipant in Cohort 2completed
his/her Day  8 visit (or discontinued earlier) .
All Cohort 2 safety  data collected up to the time the lastparticipant in Cohort 2completed
his/her Day  8 visit (or discontinued earlier) .
All Cohort 3 safet y data collected up to the time the 16thparticipa nt in Cohort 3completed
his/her Day  8 visit (or discontinued earlier) .
After these reviews, the DRC will make recommendations regarding the continuation of the 
study . Conclusions of the DRC will be communicated to the investigators, the IEC/IRB,and the 
national regulatory  authorities as appropriate. Details will be provided in a separate DRC charter.
If deemed necessary  for safet y review, the DRC may request randomization codes and review 
unblinded data, if applicable.
Safety  data from the planned analyses (Section 9.5)will be shared with the DRC.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
56
Status: Approved ,  Date: 16 March 202010. SUPPORTING DOCUMENTA TION A ND OPERA TIONA LCONSIDERA TIONS
10.1. Appendix 1: Abbrev iations
Ad26 adenovirus sero type 26
AE adverse event
BMI body mass index
CD cluster of differentiation
CI confidence interval
CTM clinical trial material
DNA deoxyribonucleic acid
DRC Data Review Committee
eCRF electronic case report form(s) 
eDC electronic data capture
ELISA enzyme -linked immunosorbent assay
ELISpot enzyme -linked immunospot
FAS Full Analysis Set
FDA Food and Drug Administration
GCP Good Clinical Practice
GMT geometric mean titer
IB Investigator ’sBrochure
ICF informed consent form
ICH International Council forHarmonisation of Technical Requirements for Pharmaceuticals for 
Human Use
ICS intracellular cytokine staining
IEC Independent Ethics Committee
IFN interferon
Ig immunoglobulin
IM intramuscular (ly)
IRB Institutional Review Board
IWRS interactive web response system
MedDRA Medical Dictionary for Regulatory Activities
NHP nonhuman primate
PI [INVESTIGATOR_233809]-protocol Immunogenicity 
PQC Product Quality Complaint
preF prefusion conformation -stabilized F protein
RSV respi[INVESTIGATOR_233810]-AUC viral load as measured by [CONTACT_233863]
(eSource) systemContains data traditionally maintained in a hospi[INVESTIGATOR_233811] e CRF as determined by [CONTACT_760]. Data in this system may 
be considered source documentation.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
57
Status: Approved ,  Date: 16 March 202010.2. Appendix 2: Toxicity  Grading Scale
Adapted from the FDA Guidance document "Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials "(September 2007) .
A: Tables for Clinical Abnormalities
Local Reaction to
Injectable ProductMild (Grade 1) Moderate (G rade2)Severe (Grade3) Potentially Life
Threat ening
(Grade4)
Pain/Tenderness#Aware of symptoms 
but easily tolerated;
Does not interfere 
with activity;
Discomfort only to 
touchNotable symptoms;
Requires modification 
in activity or use of 
medications;
Discomfort with 
movementIncapacitating 
symptoms;
Inability to do w ork, 
school, or usual 
activities; Use of 
narcotic pain relieverHospi[INVESTIGATOR_059];
Pain/tenderness 
causing inability to 
perform basic self -
care function
Erythema#25 –50 mm 51 –100 mm > 100 mm Hospi[INVESTIGATOR_059]; 
Necrosis or 
exfoliative dermatitis
Swelling#25 –50mm 51 –100 mm >100mm Hospi[INVESTIGATOR_059]; 
Necrosis
#Revised by [CONTACT_456].
Vital Signs * Mild (Grade 1) Moderate (Grade 2) Severe (Grade 3) Potentially Life
Threatening
(Grade 4)
Fever (°C) **
           (°F)**38.0 -38.4 
100.4 - 101.1 38.5 -38.9 
101.2 - 102.039.0 -40.0 
102.1 - 104.0> 40
> 104.0 
Tachycardia -beats 
per
minute101 – 115 116 – 130 > 130 Hospi[INVESTIGATOR_40674]#
Bradycardia -beats 
per
minute***50 –54 45 –49 <45 Hospi[INVESTIGATOR_40674]#
Hypertension 
(systolic) -mm Hg141 – 150 151 – 160#> 160#Hospi[INVESTIGATOR_233812]#
Hypertension 
(diastolic) -mm Hg91 –95 96 –100 > 100 Hospi[INVESTIGATOR_233812]#
Hypotension 
(systolic) –mm Hg85 –89 80 –84 < 80 Hospi[INVESTIGATOR_165074]#
Respi[INVESTIGATOR_13581] –
breaths per minute17 –20 21 –25 > 25 Intubation
Systemic (General) Mild (Grade 1) Moderate (G rade2)Severe (G rade3) Potentially Life
Threat ening
(Grade4)
Vomit ing#No interfere nce
with activity or 1 – 2 
epi[INVESTIGATOR_1841]/24 ho ursSome interfer ence
with activity or > 2 
epi[INVESTIGATOR_1841]/24 ho ursPreventsdaily
activity, req uires 
outpatient IV 
hydrationHospi[INVESTIGATOR_059]; 
Hypotensive shock
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
58
Status: Approved ,  Date: 16 March 2020Nausea#Minimal symptoms; 
causes minimal or no 
interference with 
work, school, or self -
care activitiesNotable symptoms;
Requires modification 
in activity or use of 
medications;
Does NOT result in 
loss of work, school, 
or cancellation of 
social activitiesIncapacitating 
symptoms;
Requires bed rest 
and/or results in loss 
of work, school, or 
cancellation of social 
activitiesHospi[INVESTIGATOR_059];
Inability to perform 
basic self -care 
functions
Diarrhea#2 – 3 lo osestoolsor
< 400 gms/24 hours4 – 5 st ools or
400 – 800 gms/ 24 
hours6 or morewatery
stools or
> 800 gms/24 hours 
or oral rehydration 
necessaryHosp italizati on; 
Hypotensive shock 
OR IV fluid 
replacement indicated
Headache#Minimal symptoms; 
causes minimal or no 
interference with 
work, school, or self -
care activitiesNotable symptoms;
Requires modification 
in activity or use of 
medications;
Does NOT result in 
loss of work, school, 
or cancellation of 
social activitiesIncapacitating 
symptoms;
Requires bed rest 
and/or results in loss 
of work, school, or 
cancellation of social 
activities;
Use of narcotic pain 
relieverHospi[INVESTIGATOR_059];
Inability to perform 
basic self -care 
functions
Fatigue#Minimal symptoms; 
causes minimal or no 
interference with 
work, school, or self -
care activitiesNotable symptoms;
Requires modification 
in activity or us e of 
medications;
Does NOT result in 
loss of work, school, 
or cancellation of 
social activitiesIncapacitating 
symptoms;
Requires bed rest 
and/or results in loss 
of work, school, or 
cancellation of social 
activities;
Use of narcotic pain 
relieverHospi[INVESTIGATOR_18543];
Inability to perform 
basic self -care 
functions
Myalgia#Minimal symptoms; 
causes minimal or no 
interference with 
work, school, or self -
care activitiesNotable symptoms;
Requires modification 
in activity or use of 
medications;
Does NOT result in 
loss of work, school, 
or cancellation of 
social activitiesIncapacitating 
symptoms;
Requires bed rest 
and/or results in loss 
of work, school, or 
cancellation of social 
activities;
Use of narcotic pain 
relieverHospi[INVESTIGATOR_059];
Inability to perform 
basic se lf-care 
functions
#Revised by [CONTACT_456].
Systemic Illn ess Mild (Grade 1) Mode rate (Grade2)Severe (Grade3) Potentially Life
Threat ening
(Grade4)
Illness or clin ical
adverse
event (asdefined 
according to
 No interfere nce with
activitySome interfer ence
with activity not 
requiring medical 
interventionPreventsdaily
activity and 
requires medic al 
interventionHosp italizati on#
#Revised by [CONTACT_456].
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
59
Status: Approved ,  Date: 16 March 2020B: Tables for Laboratory Abnormalities
The laboratory  values provided in the tables below serve as guidelines and are dependent upon 
institutional normal parameters. Institutional normal reference ranges should be provided to 
demonstrate that they  are appropriate.
Serum * Mild 
(Grade 1)Moderate
(Grade2)Severe
(Grade3)PotentiallyLife
Threat ening
(Grade4)**
Sodium – Hyponat remiamEq /L 132 – 134 130 – 131 125 – 129 < 125
Sodium – Hyp ernatre miamEq/L 144 – 145 14 6 – 147 14 8 – 150 > 150
Potassium–Hyperkalemia mEq/L 5. 1 – 5.2 5. 3 – 5.4 5. 5 – 5.6 > 5.6
Potassium–Hypokalemia mEq/L 3. 5 – 3.6 3. 3 – 3.4 3. 1 – 3.2 < 3.1
Gluco se–Hypoglycemiamg/dL 6 5 –69 55 –64 45 –54 < 45
Gluc ose– Hypergly cemia
  Fasti ng mg/d L 
  Random– mg /dL100 – 110
110 – 125111 – 125
126 – 200>125
>200Insulin 
require ments or 
hype rosmolar 
coma
Blood Urea Nitrogen
BUN mg/dL23 –26 27 –31 > 31 Requires dialysis
Creatinine – mg/dL 1.5 – 1.7 1. 8 – 2.0 2. 1 – 2.5 > 2. 5 or requires 
dialysis
Calcium – hypo calce miamg/dL 8.0 – 8.4 7. 5 – 7.9 7. 0 – 7.4 < 7.0
Calci um – hy percalcemia mg/dL 10 .5– 11.0 11.1 – 11.5 11.6 – 12.0 > 12.0
Magnes ium– hypomagnes emia mg/dL 1. 3 – 1.5 1. 1 – 1.2 0. 9 – 1.0 < 0.9
Phosphorous – h ypophosphatem ia mg/dL 2. 3 – 2.5 2. 0 – 2.2 1. 6 – 1.9 < 1.6
CPK – mg/dL 1.25 –1.[ADDRESS_282225]***1.6 – 3.[ADDRESS_282226] 3. 1 –[ADDRESS_282227] > [ADDRESS_282228]
Albumin– Hy poalbuminem iag/dL 2. 8 – 3.1 2. 5 – 2.7 < 2.5 --
Total Pr otein – Hypoproteinemia g/dL 5. 5 – 6.0 5. 0 – 5.4 < 5.0 --
Alkaline ph osphate –
increase by[CONTACT_12245]1.1 – 2.[ADDRESS_282229] 2. 1 – 3.[ADDRESS_282230] 3. 1 –10x ULN > [ADDRESS_282231]
Liver Functio n Tests –ALT,AST
increase by[CONTACT_12245]1.1 – 2.[ADDRESS_282232] 2. 6 – 5.[ADDRESS_282233] 5. 1 – [ADDRESS_282234] > [ADDRESS_282235]
Bilirubin –when accompan ied
by [CONTACT_233864] L iverFunctionTest 
increase by[CONTACT_12245]1.1 – 1.2 5 x 
ULN1.26 – 1.5 x 
ULN1.51 – 1.[ADDRESS_282236]> 1.[ADDRESS_282237]
Bilirubin –when LiverFunctio n Test
is nor mal; increase by [CONTACT_12245]1.1 – 1.[ADDRESS_282238] 1. 6 – 2.[ADDRESS_282239] 2. 0 – 3.[ADDRESS_282240] > 3. [ADDRESS_282241]
Cholesterol 201 – 210 211 – 225 > 226 ---
Pancreatic enzymes– amyl ase,lipase 1.1 – 1.[ADDRESS_282242] 1. 6 – 2.[ADDRESS_282243] 2. 1 – 5.[ADDRESS_282244] > 5. [ADDRESS_282245]
* The laboratory valuesprovided in the tab lesserve asguidelin es and are dependent upon institutionalnormal 
parameters. Instit utional normal refere nceranges should be providedto demonstrate that they are ap propriate.
** The clinical sig ns or symptoms associated with laboratory abnormal ities might result in ch aracterizati on of the 
laboratory abn ormalities as pote ntially life -threate ning (Grade 4). Fo r example.a low s odiumvalue th at falls 
withina Grade3 parameter (125-129 mE /L) shoul d be recorded a s a Grad e 4 hyponatremia even t if the 
participant had a new seizure a ssociated with the low sodium value.
***ULN is the u pper limit of th e normal range.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
60
Status: Approved ,  Date: 16 March 2020Hem atology* Mild 
(Grade 1)Moderate
(Grade2)Severe
(Grade3)Potentially Life
Threat ening
(Grade4)
Hemoglob in (Female)- gm/dL 11 .0 – 12.0 9. 5 – 10.9 8.0 – 9.4 < 8.0
Hemoglobin (Female)
changefrombaseli nevalue - gm/dLAny decrease – 1.5 1. 6 – 2.0 2. 1 – 5.0 > 5.0
Hemoglobin (Male)- gm/dL 12 .5 – 13.5 10 .5 – 12.4 8. 5 – 10.4 < 8.5
Hemoglob in (Male)
changefrombaseli nevalue – gm/dLAny decrease – 1.5 1. 6 – 2.0 2. 1 – 5.0 > 5.0
WBC Increa se-cell/m m310,800 – 15, 000 15, 001 – 20, 000 20, 001 – 25, 000 > 25,000
WBC Decrease - cell/m m32,500 – 3,500 1,500 – 2,499 1,000 – 1,499 < 1,000
Lymphoc ytesDecrease -cell/mm3750 – 1,000 500 – 749 250 – 499 < 250
Neutrophils D ecrease -cell/m m31,500 – 2,000 1,000 – 1,499 500 – 999 < 500
Eosinophils-cell/mm3650 – 1500 1501 - 5000 > 5000 Hypereosinophilic
Platelets Decreased -cell/m m3125,000 –140,000100,000 –
124,[ZIP_CODE],000 – 99,000 < 25,000
PT–increase by [CONTACT_233865]
(prothromb intime)1.0 – 1.[ADDRESS_282246]**1.11 – 1.2 0 x 
ULN1.21 – 1.[ADDRESS_282247] > 1.[ADDRESS_282248]
PTT –increase by[CONTACT_12245]
(partial throm boplastin time)1.0 – 1.[ADDRESS_282249] 1.2 1 – 1.4 x 
ULN1.41 – 1.[ADDRESS_282250] > 1.[ADDRESS_282251]
Fibrinogen incr ease - mg/dL 40 0 – 500 50 1 – 600 > 600 --
Fibrinoge n decrease - mg/dL 15 0 – 200 125 – 149 100 – 124 < 100 or as sociated
with g rossbleeding 
or disse minated 
intravascular 
coagulation (DIC)
* Th e labo ratory valuesprovided in the tab lesserve asguidelin es and are dependent upon institutionalnormal 
parameters. Instit utional normal refere nceranges should be providedto demonstrate that they are ap propriate.
**ULN is the upperlimit of the norm al ran ge.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
61
Status: Approved ,  Date: 16 March 202010.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
ADVERSE EVENT DEFINITIONS A ND CL ASSIFICA TIONS
AE
An AE is any untoward medical occurrence in a clinical study  participant administered a 
medicinal (investigation al or noninvestigational) product. An AE does not necessarily  have a 
causal relationship with the study  vaccine. An AE can therefore be any unfavorable and 
unintended sign (including an abnormal finding), symptom, or disease temporally  associated 
with the use of a medicinal (investigational or noninvestigational) product, whether or not related 
to that medicinal (investigational or noninvestigational) product (Definition per ICH).
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: For time period of sponsor’s AE collection, see all AEs under Section 8.3.[ADDRESS_282252] medical occurrence that at an y dose:
Results in death
Is life -threatening
(The participant was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whethe r expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_233813]. These should usually  be considered serious.
If a serious and unexpected AE occurs for which there is evidence suggesting a causal 
relationship between the study  vaccine and the event (eg, death from anaphy laxis), the event 
must be reported as a S[LOCATION_003]R by [CONTACT_233866]/IRBaccording to regulatory  and local requirements.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
62
Status: Approved ,  Date: 16 March 2020Unlisted (Unexpected) AE/Reference Safety Information
An AE is considered unlist ed if the nature or severit y is not consistent with the applicable 
product reference safet y information. For the Ad26/protein preF RSV vaccine , the expectedness 
of an AE will be determined by  [CONTACT_233867].
ATTRIBUTION DEFINITIONS
Causality  of AEs should be assessed b y the investigator based on the following:
Related : there is a reasonable possibility  that the study  vaccine contributed to the AE.
Unrelated : there is no suspi[INVESTIGATOR_177872] a relationship between the study vaccine and the 
AE; there are other more likely  causes and administration of the study  vaccine is not suspected to 
have contributed to the AE.
By [CONTACT_108], all solicited AEs at the injection site will be considered related to the study  
vaccine admin istration.
SEVERITY CRITERIA
All AEs and laboratory  data will be coded for severit y using a modified version of the FDA 
grading table, based on version of September 200716, included in Section 10.2, Appendix 2.
For AEs not identified in the grading table, the following guidelines will be applied:
Grade [ADDRESS_282253] on a sponsor study  vaccine in an interventional study  that may require 
expedited reporting or safety  evaluation include, but are not limited to:
Overdose of a sponsor study  vaccine
Suspected abuse/misuse of a sponsor stud y vaccine
Accidental or occupational exposure to a sponsor study  vaccine
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
63
Status: Approved ,  Date: 16 March 2020Medication error, intercepted medication error, or potential medication error involving a 
[COMPANY_012] medicinal product (with or without patient exposure to the Johnson & 
Johnson medicinal product, eg, product name [CONTACT_2976], product label confusion, 
intercepted prescribing or dispensing errors)
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of an SAE should be recorded on the SAE page of the eCRF.
PROCEDURES
All AEs
All AEs, regardless of seriousness, severity , or presumed relationship to study  vaccine, must be 
recorded using medical terminology  in the source document and the eCRF. Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common etiology  (eg,cough, 
runny  nose, sneezing, sore throat, and head congestion should be reported as "upper respi[INVESTIGATOR_28945]"). Investigators must record in the eCRF their opi[INVESTIGATOR_233814]. All measures required for AE management must be recorded in the 
source document and reported according to sponsor instructions.
For all studies with an outpatient phase, including open -label studies, the participant must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study  number
Statement, in the local language(s), that the participant is participating in a clinical study
Investigator ’s name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local sponsor ’s name [INVESTIGATOR_1238] [ADDRESS_282254] telephone number (for medical personnel onl y)
Study  site number
Participant number
Any other information that is required to do an emergency  breaking of the blind
SAEs
All SAEs that have not resolved by [CONTACT_2054] , or that have not resolved upon 
discontinuation of the participant ’s participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  vaccine or to factors unrelated to 
study  conduct
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
64
Status: Approved ,  Date: 16 March 2020It becomes unlikel y that any additional information can be obtained (particip ant or health 
care practitioner refusal to provide additional information, lost to follow -up after 
demonstration of due diligence with follow -up efforts)
Suspected transmission of an infectious agent by  a medicinal product will be reported as an SAE. 
Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs during the 
course of a participant ’s participation in a study  must be reported as an SAE , except 
hospi[INVESTIGATOR_23741]:
Hospi[INVESTIGATOR_43717] (eg, social reasons such as 
pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF). Note: Hospi[INVESTIGATOR_23743], and where 
the underl ying condition for which the hospi[INVESTIGATOR_23744], will 
not be considered SAEs. Any AE that results in a prolongation of the originall y planned 
hospi[INVESTIGATOR_23745] a new SAE.
The cause of death of a participant in a study  during the entire study  period, whether or not the 
event is expected or associated with the study vaccine, is considered an SAE and must be 
reported.
CONTA CTING SPONSOR REGA RDING SAFETY
The names (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
PQC HA NDLING
APQC is defined as any suspi[INVESTIGATOR_1884] a product defect related to manufacturing, labeling, or 
packaging, ie, any dissatisfaction relative to the identity , quality , durability , or reliability  of a 
product, including its labeling or package integrity . A PQC ma y have an impact on the safet y and 
efficac y of the product. Timely , accurate, and complete reporting and analy sis of PQC 
information from studies are crucial for the protection of participants, investigators, and the 
sponsor , and are mandated by [CONTACT_67819]. The sponsor has established 
procedures in conformity  with regulatory  requirements worldwide to ensure appropriate 
reporting of PQC information; all studies conducted by [CONTACT_97536].
Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_282255] report the PQC to the 
spons or according to the SAE reporting timelines (Section 8.3.1 ). A sample of the suspected 
product should be maintained for further investigation if requested b y the sponsor .
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
65
Status: Approved ,  Date: [ADDRESS_282256] Quality
The names (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provided as a separate document.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
66
Status: Approved ,  Date: 16 March 202010.4. Appendix 4: Regulatory , Ethical, and Study Oversight Considerations
REGULA TORY AND ETHICA L CONSIDERA TIONS
Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human participants. 
Compliance with this stand ard provides public assurance that the rights, safety , and well -being of 
study  participants are protected, consistent with the principles that originated in the Declaration 
of Helsinki, and that the study  data are credible.
Protocol Amendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by [CONTACT_456]. All protocol amendments must be issued by  [CONTACT_456], and signed and dated by 
[CONTACT_093]. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary  to eliminate immediate hazards to the participants, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
sponsor. When the change(s) involve only logistic or administrative aspects of the study , the 
IEC/IRB (where required) only  needs to be notifie d.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_233868](s), which will be provided as a separate 
document. Except in emergency  situations, this contact [CONTACT_23848]. In all cases, contact [CONTACT_233869]. The data recorded 
in the eCRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
67
Status: Approved ,  Date: [ADDRESS_282257] be provided to the sponsor before shipment of vaccines to the 
study  site:
 Protocol and amendment(s), if an y, signed and dated by [CONTACT_978](s).
 A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, participant compensation programs. This approval must clearly identify  the 
specific protocol by [CONTACT_23850] (or sealed, where appropriat e per 
local regulations) b y the chairman or authorized designee.
 Name [CONTACT_23875]/I RB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/IRB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748] .
 Regulatory  authority  approval or notification, if applicable .
 Signed and dated statement of investigator (eg, Form FDA 1572), if applicable .
 Documentation of investigator qualifications (eg, curriculum vitae).
 Completed investigator financial disclosure form from the PI(s), where required.
 Signed and dated clinical trial agreement, which includes the financial agreement .
Any other documentation required b y local regulations.
The following documents must be provided to the sponsor before enrollment of the first 
participant:
 Completed investigator financial disclosure forms from all subinvestigators .
 Documentation of subinvestigator qualifications (eg,curriculum vitae).
 Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable .
 Local laboratory  documentation demonstrating competence and test reliabil ity 
(eg,accreditation/license), if applicable.
IECor IRB
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]):
 Final protocol and, if applicable, amendments
 Sponsor -approved ICF (and any  other written materials to be provided to the participants)
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
68
Status: Approved ,  Date: 16 March 2020 IBs (or equivalent information) and amendments/addenda
 Sponsor -approved participant recruiting materials
 Information on compensation for study -related injuries or payment to participants for 
participation in the study , if applicable
 Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
 Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for participants
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for participants, data,or study  conduct, unless required locally ), the ICF, 
applicable recruiting materials, and participant compensation programs, and the sponsor has 
received a copy  of this approval. This approval letter must be dated and must clearly  identify  the 
IEC/IRB and the documents being approved.
During the study ,the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
 Protocol amendments (excluding the ones that are purely administrative, with no 
consequences for participants, data, or study  conduct)
 Revision(s) to I CF and any  other written materials to be provided to participants
 If applicable, new or revised participant recruiting materials approved by  [CONTACT_456]
 Revisions to compensation for study -related injuries or payment to participants for 
participation in the study , if applicable
 New edition(s) of the IB(s)and amendments/addenda
 Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB(at 
least annuall y)
 Reports of AEs that are serious, unlisted/unexpected, and associated with the study  vaccine.
 New information that may adversel y affect the safet y of the participants or the conduct of 
the study
 Deviations from or changes to the protocol to eliminate immediate hazards to the 
participants
 Report of deaths of participants under the investigator's care
 Notification if a new investigator is responsible for the study  at the study  site
 Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
69
Status: Approved ,  Date: 16 March 2020For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for participants, data,or study  conduct) , the amendment and applicable ICF 
revisions must be submi tted promptly  to the IEC/I RB for review and approval before 
implementation of the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion.
Other Ethical Considerations
For stud y-specific ethical design considerations, refer to Section 4.2.1 .
FINA NCIA L DISCLOSURE
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory  authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study  and for oneyear after com pletion of the study .
Refer to Required Prestudy  Documentation (above) for details on financial disclosure.
INFORMED CONSENT PROCESS
Each participant must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any 
study -related activity . The ICF(s) that is/are used must be approved by [CONTACT_43771]/I RB and be in a language that the participant can read and understand. 
Theinforme d consent should be in accordance with principles that originated in the Declaration 
of Helsinki, current ICH and GCP guidelines, applicable regulatory  requirements, and sponsor 
policy .
Before enrollment in the study , the investigator or an authorized memb er of the study -site 
personnel must explain to potential participants the aims, methods, reasonabl y anticipated 
benefits, and potential hazards of the study ,and any discomfort participation in the study  may 
entail . Participants will be informed that their participation is voluntary and that they may 
withdraw consent to participate at any time. They  will be informed that choosing not to 
participate will not affect the care the participant will receive. Finally , they will be told that the 
investigator will maintain a participant identification register for the purposes of long-term 
follow -up if needed and that their records may be accessed by [CONTACT_90819], to the extent permitted 
by [CONTACT_6983](s) or regulations. By [CONTACT_233870] . It also denotes that the participant agrees to allow his or her study  physician to recontact 
[CONTACT_233871] g consent for additional safet y evaluations, if needed.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
70
Status: Approved ,  Date: 16 March 2020The participant will be given suf ficient time to read the I CF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by[CONTACT_67824] ’s personall y dated signature. After having obtained the consent, a 
copy  of the ICF must be given to the participant.
DATA PROTECTION
Privacy of Personal Data
The collection and processing of personal data from participants enrolle d in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of participants confidential.
The informed consent obtained from the participant includes explicit consent for the processing 
of personal data and for the investigator/instituti on to allow direct access to his or her original 
medical records (source data/documents) for study -related monitoring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The participant has the right to request through the investigator access to his or her personal data 
and the right to request rectification of any data that are not correct or complete. Reasonable 
steps will be taken to respond to such a request, taking into consideration the nature of the 
request, the conditions of the study , and the applicable laws and regulations.
LONG -TERM RETENTION OF SA MPLES FOR ADDITION AL FUTURE RESEA RCH
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand Ad26.RSV.preF 
and RSV preF protein, to understand RSV and other respi[INVESTIGATOR_233815] , and to develop 
tests/assays related to Ad26.RSV.preF, RSV preF protein, andRSV disease . The research may 
begin at any time during the study  or the poststudy  storage period. Included are samples from 
participants who were screened but notrandomized which may also be used to develop 
tests/assay s related to Ad26.RSV.preF, RSV preF protein, and RSV disease .
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Participants may withdraw their consent for their samples to be 
stored for research (Section 7.4.1 ).
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
71
Status: Approved ,  Date: 16 March 2020COMMITTEES STRUCTURE
Data Review Committee
A DRC will be established for this study (Section 9.6).
PUBLICA TION POLICY /DISSEMINA TION OF CLINICA L STUDY DA TA
All information, including but not limited to information regarding the Ad26/protein preF RSV 
vaccine or the sponsor ’s operations (eg,patent application, formulas, manufacturing processes, 
basic scientific data, prior clinical data, formulation information) supplied by [CONTACT_170193], and any data, generated as a result of this study , are
considered confidential and remain the sole property  of the sponsor. The investigator agrees to 
maintain this information in confidence and use this information only to accomplish this study  
and will not use it for other purposes without the sponsor ’s prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_233872]26/protein preF RSV vaccine , 
and thus may be disclosed as require d to other clinical investigators or regulatory  agencies. 
Topermit the information derived from the clinical studies to be used, the investigator is 
obligated to provide the sponsor with all data obtained in the study .
The results of the study  will be reported in a clinical study report generated by [CONTACT_66896]. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator [INVESTIGATOR_25810] . Results of analy ses 
performed after the clinical study report has been issued will be reported in a separate report and 
will not require a revision of the clinical study report.
Study  participant identifiers will not be used in publication of results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by [CONTACT_233873]) shall be 
the propert y of the sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors (ICMJE) guidelines, the sponsor shall have the right to publish such primary 
(multicenter) data and information without approval from the investigator. The investigator has 
the right to publish study site -specific data after the primary  data are published. If an i nvestigator 
wishes to publish information from the study ,a copy  of the manuscript must be provided to the 
sponsor for review at least 60days before submission for publication or presentation. Expedited 
reviews will be arranged for abstracts, poster prese ntations, or other materials. If requested by 
[CONTACT_97533], the investigator will withhold such publication for up to an additional 
60days to allow for filing of a patent application. In the event that issues arise regarding 
scientific integrity or regulatory  compliance, the sponsor will review these issues with the 
investigator. The sponsor will not mandate modifications to scientific content and does not have 
the right to suppress information. For multicenter study  designs and sub-study  approac hes, 
secondary  results generally  should not be published before the primary  endpoints of a study  have 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
72
Status: Approved ,  Date: [ADDRESS_282258] made a significant contribution to the conception or design of the work; or the acquisition, 
analysis, orinterpretation of the data for the work; and drafted the work or revised it critically  for 
important intellectual content; and given final approval of the version to be published; and 
agreed to be accountable for all aspects of the work in ensuring that questions related to the 
accuracy  or integrity  of any  part of the work are appropriatel y investigated and resolved .
Registration of Clinical Studies and D isclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law .
DATA QUA LITY ASSURA NCE
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , and periodic monitoring visits by [CONTACT_456]. Written 
instructions will be pr ovided for collection, handling, storage, and shipment of samples.
Guidelines for eCRF completion will be provided and reviewed with study -site personnel before 
the start of the stud y.
The sponsor will review eCRF for accuracy  and completeness during on-site monitoring visits 
and after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they  will be verified for 
accuracy  and consistency with the d ata sources.
CASE REPORT FORM COMPLETION
Case report forms are prepared and provided by [CONTACT_90824]. All eCRF entries, corrections, and alterations must be made by [CONTACT_154913] -site personnel. The investigator must verify  that all data entries in the eCRF are 
accurate and correct.
The study  data will be transcribed by [CONTACT_3449]-site personn el from the source documents onto an 
eCRF, if applicable. Study-specific data will be transmitted in a secure manner to the sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. 
Any such worksheets will become part of the participant ’s source documents. Data must be 
entered into the eCRF in English. The eCRF must be completed as soon as possible after a 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
73
Status: Approved ,  Date: [ADDRESS_282259] s:
Investigator and study -site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]).
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_23858] -site personnel.
SOURCE DOCUMENTS
At a minimum, source documents consistent in thetype and level of detail with that commonly  
recorded at the study  site as a basis for standard medical care must be available for the following: 
participant identification, eligibility , and study  identification; study  discussion and date of signed 
informe d consent; dates of visits; results of safety  and immunogenicity  parameters as required by  
[CONTACT_760]; record of all AEs and follow -up of AEs ; concomitant medication; vaccine 
receipt/dispensing/return records; study  vaccine administration information ; and date of study 
completion and reason for early discontinuation of study  vaccination or withdrawal from the 
study , if applicable.
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring 
guidelines (or other equivalent document).
The following participant -and investigator -completed assessments will be recorded and will be 
considered source data:solicited AEs after vaccination andbody  temperature. The participant 
diary used to collect information regarding solicited signs and symptoms after vaccination will 
be considered source data.
An eSource system may be utilized, which contains data traditionally  maintained in a hospi[INVESTIGATOR_90761] (eg, electronic source documents) as well as the clinical 
study -specific data fields as determined by [CONTACT_760]. This data is electronical ly extracted for 
use by [CONTACT_456]. If eSource is utilized, references made to the eCRF in the protocol include 
the eSource system but information collected through eSource may not be limited to that found 
in the eCRF. Data in the eSource system may be co nsidered source documentation.
MONITORING
The sponsor will use a combination of monitoring techniques (central , remote, or on-site 
monitoring )to monitor this study .
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study -site visit log that will be kept at the study  site. The first 
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
74
Status: Approved ,  Date: [ADDRESS_282260]-initiation visit will be made as soon as possible after enrollment has begun. At these visits, 
the monitor will compare the data entered into the eCRF with the source documents 
(eg,hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records) ; a sample may be reviewed .The nature 
and location of all source documents will be identified to ensure that all sources of original data 
required to complete the eCRF are known to the sponsor and study -site personnel and are 
accessible for verification by [CONTACT_43786] -site contact. If electronic records are maintained 
at the study  site, the method of verification must be discussed with the study -site personnel.
Direct access to source documents (medical records) must be allowed for the purpose of 
verify ing that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study -site personnel. The sponsor expe cts that, during 
monitoring visits, the relevant study -site personnel will be available, the source documents will 
be accessible, and a suitable environment will be provided for review of study -related 
documents. The monitor will meet with the investigator on a regular basis during the study to 
provide feedback on the study conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these remote contacts, study -site personnel will be available to provide an updat e on the progress 
of the study  at the study  site.
Central monitoring will take place for data identified by  [CONTACT_70467].
ON-SITE A UDITS
Representatives of the sponsor ’s clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study
records, including source documents, for inspection. Participant privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and 
available for consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_103].
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investi gator should immediately  notify  the sponsor if he or she has 
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
RECORD RETENTION
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected from each participant, as well as all 
study  documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_233874](s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
75
Status: Approved ,  Date: [ADDRESS_282261]. These documents will be 
retained for a longer period if required by [CONTACT_43785]. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibi lity of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator/institution must permit access to such 
reports.
STUDY AND SITE START A ND CLOSURE
First Act of Recruitment
The first study  site open is considered the first act of recruitment and it becomes the study  start 
date.
Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. 
Astudy  site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of a study  site by [CONTACT_11004]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor’ s procedures, or GCP guidelines
Inadequate recruitment of participants b y the investigator
Discontinuation of further study  vaccine development
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
76
Status: Approved ,  Date: 16 March 202010.5. Appendix 5: Protocol A mendment History
This is an original protocol.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
77
Status: Approved ,  Date: 16 March 202011. REFERENCES
1. Adenoviral Vaccine Safety Database. Version 4.0. Janssen Vaccines & Prevention B.V. (May  2019).
2. Barouch DH, Liu J, Peter L, et al. Characterization of humoral and cellular immune responses elicited by a 
recombinant adenovirus serotype 26 HIV -1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 
2013 ;207:248- 256.
3. Barouch DH, Tomaka FL, Wegmann F, et al. Evaluation of a mosaic HIV -1 vaccine in a multicentre, 
randomised, double -blind, placebo -controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys 
(NHP 13 -19).Lancet. 2018;392([ZIP_CODE]):232 -243.
4. de Bree GJ, Heidema J, van L eeuwen EM, et al. Respi[INVESTIGATOR_4345] -specific CD8+ memory T cell 
responses in elderly persons. J Infect Dis. 2005:191;1710 -1718.
5. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respi[INVESTIGATOR_233816] -risk adults. N Engl J Med. 2005 ;352(17): 1749 -1759.
6. Falsey AR, Walsh EE. Respi[INVESTIGATOR_4445]. Clin Microbiol Rev. 2000; 13(3):371-
384.
7. Gidudu JK, Walco GA, Taddio A, et al./The Brighton Immunization Site Pain Working Group. Immunization
site pain: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. 
Vaccine. 2012 ;30(30): 4558 -4577.
8. Investigator ’s Brochure: Ad26.RSV.preF (JNJ -64400141). Edition 10 . Janssen Vaccines & Prevention B.V.
(Decemb er 2019). 
9. Investigator ’s Brochure: RSV preF protein (JNJ -64213175). Edition 4 . Janssen Vaccines & Prevention B.V.
(December 2019) .
10. Janssen Vaccines & Prevention B.V (data on file) .
11. Kohl KS, Walop W, Gidudu J, et al. ;Brighton Collaboration Local Reaction Working Group for Swelling at or 
near Injection Site. Swelling at or near injection site: case definition and guidelines for collection, analysis and 
presentation of immunization safety data. Vaccine 2007 ;25(31);5858-5874.
12. Lee FE, Walsh EE, Falsey AR, et al. The balance betw een influenza -and RSV -specific CD4 T cells secreting 
IL-10 or IFNgamma in young and healthy -elderly subjects. Mech Ageing Dev. 2005:126;[ADDRESS_282262] Dis. 2002 ;185:682- 685.
14. Marcy SM, Kohl KS, Dagan R, et al. ; Brighton Collaboration Fever Working Group. Fever as an adverse event 
following immunization: case definition and guidelines of data collect ion, analysis, and presentation. Vaccine 
2004;22:551 -556.
15. Milligan ID, Gibani MM, Se well R, et al. Safety and immunogenicity of novel adenovirus type 26 -and 
modified vaccinia ankara -vectored ebola vaccines: a randomized clinical trial. JAMA. 2016 ;315:1610 -1623.
16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics 
Evaluation and Research. September 2007. Guidance for Industry. Toxicity Grading Scale for Healthy Adult 
and Adolescent Volunteers Enrolled in Preventiv e Vaccine Clinical Trials. Available from: 
https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidan
ces/Vaccines/ucm091977.pdf . Accessed: 17 February 2020.
17. U.S. Department of Health and Human Services, Food and Dru g Administration. March 2018. Conditions for 
IRB Use of Expedited Review. Available from :
https://www fda.gov/ScienceResearch/SpecialTopi[INVESTIGATOR_1102]/RunningClinicalTrials/GuidancesInformationSheetsandN
otices/ucm118099.htm . Accessed : 14 February 2020 .
18. U.S. Department of Health and Human Services ,Office for Human Research Protections . March 2016. OHRP 
Expedited Review Categories (1998) . Available from : http://www.hhs.gov/ohrp/regulations -and-
policy/guidance/categories -of-research -expedited -review -procedure -1998/index.html. Accessed :14 February
2020.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
78
Status: Approved ,  Date: [ADDRESS_282263] Dis. 2004 ;190:373- 378.
VAC18193 (JNJ -64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
79
Status: Approved ,  Date: [ADDRESS_282264] of the study, and the obligations of confidentiality.
Coordinating Investigator (where required):
Nam e (typed or printed):
Institution and Address:
Signature: [CONTACT_1782]:
(Day Month Year)
Principal (Site) Investigator:
Nam e (typed or printed):
Institution and Address:
Telephone Number:
Signature: [CONTACT_1782]:
(Day Month Year)
Sponsor ’sResponsible Medical Officer:
Nam e (typed or printed):
Institution: Janssen Vaccines & Prevention B.V.
Signature: [CONTACT_184956]:
(Day Month Year)
Note: If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by [CONTACT_68477], and a protocol amendment will not be required.
[COMPANY_003]
  
SIGNATURES 
    
Signed by  [CONTACT_111198]  
   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
16Mar2020, 16:29:52 PM, UTC
Document Approval
[COMPANY_003]
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,  Date: 11 June 2020Janssen Vaccines & Prevention B.V.*
Clinical Protocol
COVID -19 Appendix
Protocol Title
A Randomized, Double -blind, Placebo -controlled Phase 2a Study to Evaluate a Range of 
Dose Levels of an Ad26.RSV.preF -based Vaccine in Adults Aged 60 Years and Older
Protocol VAC18193RSV2005 ; Phase 2a
VAC18193 (JNJ -64400141/JNJ-64213175)  
*Janssen Vaccines & Prevention B.V. is a Janssen pharmaceutical company of [COMPANY_012] and is hereafter
referred to as the sponsor of the study. The sponsor is identified on the Contact [CONTACT_233875].
[LOCATION_002] (U S)sites of t his study  will be conducted under US Food & Drug Administration
Investi gational New Drug ( IND) regulations (21 CFR Part 312).
Status: Approved   
Date: 11 June 2020
Prepared by: [CONTACT_130328] & Prevention B.V.
EDMS number: EDMS- RIM-[ZIP_CODE], 1.0
THIS APPENDIX APPLIES TO ALL CURRENT APPROVED VERSIONS OF PROTOCOL
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company
customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipi[INVESTIGATOR_70281], regulations, rules, protective orders or 
otherwis e.
[STUDY_ID_REMOVED]
COVID -19 Appendix
VAC18193 (JNJ-64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Status: Approved ,  Date: [ADDRESS_282265] DURING THE COVID- 19 PA NDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study due to, for example, self -isolation/quarantine by  [CONTACT_90830] -site personnel; travel restrictions/limited access to public places, including hospi[INVESTIGATOR_600]; study  
site personnel being reassigned to critical tasks. 
In alignment with recent health authority  guidance, the sponsor is providing options for study  
related participant management in the event of disruption to the conduct of the study . This guidance 
does not supersede any local or government requirements or the clinical judgement of the 
investigator to protect the health and well- being of participants and site staff. If, at any time, a 
participant’s safet y is considered to be at risk, study  intervention will be discontinued, and study 
follow -up will be conducted.
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotel y/virtually  or delayed until such time that on-site visits can be resumed. At each 
contact, participants will be interviewed to collect safet y data. Key immunogenicity endpoint 
assessments should be performed if required and as feasible. Participants will also be questioned 
regarding general health status to fulfill any  physical examination requirement. 
Every  effort should be made to adhere to protocol -specified assessments for participants on study 
intervention, includi ng follow up. Modifications to protocol -required assessments may be 
permitted via COVID -19 Appendix after consultation with the participant, investigator, and the 
sponsor. Missed assessments/visits will be captured in the clinical trial management system for 
protocol deviations. Discontinuations of study  interventions and withdrawal from the study  should 
be docum ented with the prefix “COVID-19 -related” in the case report form (CRF) . 
The sponsor will continue to monitor the conduct and progress of the clinical study , and any 
changes will be communicated to the sites and to the health authorities according to local guidance.  
If a participant has tested positive for COVID -19, the investigator should contact [CONTACT_456]’s 
responsible medical officer to discuss plans for study  intervention and follow -up. Modifications 
made to the study  conduct as a result of the COVID -19 pandemic should be summarized in the 
clinical study  report.
COVID -19 Appendix
VAC18193 (JNJ-64400141/JNJ -64213175) Clinical Protocol VAC18193RSV2005
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Status: Approved ,  Date: 11 June 2020GUIDANCE SPECIFIC TO THIS PROTOCOL :
Screening and Randomization
Enrollment of new participants may continue based on the investigator’s assessment ofrisks 
versus benefits, depending on the situation at a particular site, and the ability  to monitor 
participant safety . 
Baseline visits for participants recentl y screened for this study  should be postponed ifthe 
current situation does not allow for an orderl y conduct of the study .
Site Visits
When site visits are not possible due to local/national guidelines, sites should collect the 
assessments via telephone visits or home -based visits, if the participant allows. The actual 
visit date and the type of visit (ie, telephone or home -based visit) should be captured in the 
eCRF according to the eCRF completion guidelines. Procedures that cannot be performed 
during a home -based visit (eg, clinical assessments, blood samples, nasal samples and 
physical examination), should be excluded. 
Vaccine Administration
When planning for vaccination visits, local/national or institutional guidelines will be 
followed. The study  vaccine must be administered by [CONTACT_1629] (unblinded) pharmacist or other 
qualified individual at the study  site. If this is not possible, a solution may be considered in 
consultation with the sponsor and taking into consideration participant safety. 
Informed Consent Form
Consenting and re-consenting of participant s for the measures taken (including also remote 
consenting b y phone or video consultation) will be performed as applicable and according to 
local guidance for informed consent applicable during the COVID -19 pandemic. The process 
isto be documented in the source documents.
Source Data Verification/Monitoring
In case on-site monitoring visits are not be possible, the site monitor may contact [CONTACT_233876] y (in accordance with site and 
local requirements). Additional on -site monitoring visits may  be needed in the future to catch 
up on source data verification.
Site A udits
During the COVID -[ADDRESS_282266]/engagement from the investigator and study site personnel would not be conducted in 
order to comply  with national, local, and/or organizational social distanci ng restrictions. 
Additional quality  assurance activities such as remote audits or focused review of study 
related documents may  take place with limited impact/engagement if possible.